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1.1 Cancer&Cancer,& broadly& defined& as& abnormal& cells& that& grow& and& divide& uncontrollably,& is&the&second&leading&cause&of&death&in&the&U.S.&with&more&than&500,000&deaths&in&2009&(1).&&In&general,& cancers& are& caused& by& a& series& of& genetic& abnormalities& including& mutations& of&tumor& suppressors,& like& p53,& transcriptional& or& translational&mechanisms& that& cause& the&overexpression& of& survival& proteins,& like& heat& shock& protein& 27& (Hsp27),& and& splicing&mechanisms& that& can&alternate& the& ratios&of&proQ&and&antiQapoptotic&proteins,& such&as& the&cellular&FLICEQinhibitory&protein& (cQFLIP& long&vs.& short)& (2Q5).& &These&mutations& result& in&transformed& cells& with& prolonged& lifespan,& which& resist& the& normal& signals& that& induce&programmed& cell& death,& or& apoptosis.& & Treatments& vary&depending& on& the& type& of& cancer&and&how&early& it& is&detected,&but&could& include&surgery,&chemotherapy,&radiation&therapy,&and&palliative&care&(6).&Lung&cancer&has&both&the&highest&rate&of&incidence&as&well&as&the&greatest&mortality&rate&of&any&cancer&in&the&U.S.&with&200,000&new&cases&and&a&75%&mortality&rate&in&2010&(7).&&Lung& cancers& are& divided& histologically& into& small& cell& lung& carcinomas& (SCLC)& and& nonQsmall&cell& lung&carcinomas&(NSCLC).& &NSCLC&account& for&85%&of&all& lung&cancer&cases&and&are& further&subdivided& into&adenocarcinomas&(AC,&40%),&squamous&cell& carcinomas&(SCC,&40%),&and& large&cell&carcinomas&(LCC,&20%)&(8,9).& &Approximately&70%&of&all&NSCLCs&are&diagnosed&in&the&advanced&stage&in&which&the&cancer&has&already&begun&to&metastasize&from&the&lung&to&other&organs&of&the&body,&including&local&lymph&nodes&and&the&brain&(8).&&Once&
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NSCLCs&have&progressed&to&the&advanced&stage,&the&fiveQyear&survival&rate&is&less&than&1%&with& limited& treatment& options,& including& combination& chemotherapy& and& palliative&radiation& therapy& (10).& & Cancer& cells& killed& by& combination& chemotherapies& involving&platinum& agents& like& cisplatin& (DNA& damage),& mitotic& inhibitors& including& paclitaxel,&vinorelbine,&and&docetaxel&(cell&cycle&arrest),&nucleoside&analogs&such&as&gemcitabine&(DNA&damage),&and& folate&antiQmetabolites& like&pemetrexed&(disruption&of&DNA&synthesis)&have&only&been&shown&to&extend&survival&by&two&months&while&greatly&decreasing&the&quality&of&life&due&to&the&toxic&side&effects&of&multiple&chemotherapeutic&agents&(11).&&As&a&result&of&the&high& mortality& rate& and& ineffectiveness& of& treatments,& there& has& been& recent& interest& in&identifying&novel&therapies&for&the&treatment&of&NSCLCs.&&
1.2 Apoptosis!and!Apoptotic!Regulators&Apoptosis& is& the& evolutionarily& conserved& mechanism& of& cell& death& essential& for&normal& organismal& development& and& cellular& homeostasis& (12).& & This& tightly& controlled&biological&process&involves&numerous&proteins&and&pathways,&but&it&is&primarily&regulated&by&a&family&of&conserved&cysteine&proteases&known&as&the&caspases.&&The&first&caspase&to&be&identified&was&cedQ3&and&was&discovered& in&C.% elegans% (13).& & Since& that& time,&13&caspases&have&been&identified&in&mammals,&12&of&which&can&be&found&in&humans&(caspaseQ11&being&the&exception).&&Caspases&play&a&variety&of&roles,&not&limited&to&apoptosis,&by&contributing&to&normal&development&and&inflammation.&&Within&apoptosis,&caspaseQ8&and&Q9&are&known&as&initiator& caspases,& which& transmit& the& apoptotic& signal& to& caspaseQ3,& Q6,& and& Q7,& the&executioner&caspases,&which&receive&the&signal&and&are&responsible&for&the&biochemical&and&physiological& changes& that& occur& in& an& apoptotic& cell& including& DNA& fragmentation,&
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cytoplasmic& shrinkage,& and&membrane&blebbing& (12,14).& &All& caspases& are& synthesized&as&inactive& zymogens& (or& procaspases)& and& require& proteolytic& maturation& to& exhibit&enzymatic&activity.&&&Apoptotic& signaling& occurs& via& the& intrinsic& and& extrinsic& pathways.& & The& extrinsic&pathway& involves& the& binding& of& a& ligand& to& a& death& receptor.& & The&most& studied& ligands&include& Fas& and& tumor& necrosis& factor& (TNF)& family& members& TNFα& and& TNFQrelated&apoptosis&inducing&ligand&(TRAIL),&which&bind&to&the&receptors&CD95,&TNFQR1&and&QR2,&and&death&receptors,&DR4&and&Q5&(15Q18).&&The&ligand&binding&results&in&the&recruitment&of&the&FasQassociated&death&domain&(FADD)&protein&and&procaspaseQ8&within&the&cell,&which&forms&the& death& inducing& signaling& complex& (DISC)& leading& to& activation& of& caspaseQ8& (Fig.& 14)&(17,19).& & The& intrinsic& pathway& is& initiated& by& cellular& stress,& such& as& DNA& damage& or&reactive&oxygen&species&(ROS),&often&caused&by&a&chemotherapeutic&drug&or&UV&irradiation.&&The& stimulus& promotes& mitochondrial& membrane& depolarization& and& the& release& of&cytochrome&C,&which&forms&a&complex&with&apoptotic&protease&activating&factor&1&(APAFQ1)&and&procaspaseQ9& called& the& apoptosome& (20).& & The& association&of&procaspaseQ9&with& the&apoptosome&promotes&the&activation&of&caspaseQ9,&which&in&turn&initiates&the&activation&of&caspaseQ3&(Fig.&14)&(21Q23).&&&CaspaseQ3& is& composed&of& three&domains,&an&aminoQterminal& (NQterminal)&domain,&also&known&as&the&prodomain,&consisting&of&28&amino&acids&(aa),&a&middle&domain&of&17&kDa&(p17),&and&a&carboxyQterminal&(CQterminal)&12&kDa&domain&(p12).& &Activation&begins&with&the&enzymatic&cleavage&of& the&p12&domain&by&caspaseQ8&or& Q9&at&Asp175,& followed&by& the&autocatalytic&cleavage&of&the&prodomain.&&Two&p17&and&two&p12&subunits&reorganize&into&a&heterodimer&to& form&the&active&enzyme&(Fig.&14)&(12,19,21).& &The&active&site& is& formed&by&
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four& loops& (L1QL4)&with& L1& and&most& of& L2& found& in& the& p17& domain& and& the& remaining&loops&being&contributed&by&the&p12&domain&(24).&&The&p17&domain&also&contains&the&active&cysteine& residue& (Cys163)&within& the&L2& loop,&which&can& render& caspaseQ3& inactive&when&mutated&(24).&&The&active&heterodimer&of&caspaseQ3&then&cleaves&numerous&target&proteins&that&result&in&the&biochemical&and&physiological&changes&associated&with&apoptosis.&Although& the& extrinsic& and& intrinsic& pathways& function& independently,& a& potential&crosstalk& mechanism& between& the& two& signaling& pathways& that& leads& to& caspaseQ3&activation& has& been& reported& (25).& & In& particular,& caspaseQ8& has& been& shown& to&proteolytically&process&the&BH3&interactingQdomain&death&agonist&(BID),&a&BQcell&lymphoma&2&(BclQ2)&protein&family&member,&resulting&in&the&accumulation&of&cleaved&tQBid,&which&reQlocalizes& to& the& mitochondria& to& bind& to& BclQ2Qassociated& X& protein& & (Bax)& or& BclQ2&homologous& antagonist/killer& (Bak)& and& cause& depolarization& of& the& mitochondrial&membrane& (Fig.& 14)& (25,26).& & Regardless& if& the& extrinsic& and/or& intrinsic& pathways& are&involved,& they&both&converge&at& the& level&of&effector&caspase&activation,&making&caspaseQ3&pivotal&to&the&execution&of&apoptosis.&Excessive& apoptosis& is& believed& to& be& the& cause& of& several& autoimmune& and&neurodegenerative& disorders,& such& as& arthritis& or& Alzheimer’s.& & Conversely,& diseases& like&cancer&are&characterized&by&insufficient&apoptosis.&&Therefore,&multiple&checkpoints&tightly&regulate& this& process& to& ensure& the& proper& execution& of& apoptosis.& & In& particular,& a&repertoire&of&antiQapoptotic&proteins,&including&members&of&the&BclQ2&family,&the&inhibitors&of& apoptosis& (IAPs),& and& the& heat& shock& protein& (Hsps)& have& emerged& as& important&regulators&within&the&apoptotic&pathway.&
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So&far,&15&BclQ2&proteins&have&been&identified&in&mammalian&cells,& the&best&studied&being& the& antiQapoptotic& BclQ2& and& BQcell& lymphomaQextra& large& (BclQXL),& and& the& proQapoptotic&Bax&and&Bak&(27).& &BclQ2&and&BclQXL&maintain&the& integrity&of& the&mitochondrial&membrane& by& binding& to& the& proQapoptotic& Bax& and& Bak&molecules,& thereby& providing& a&mechanism&by&which&cell&death&or&survival&signals&are&determined&by&the&ratio&of&proQ&and&antiQapoptotic&BclQ2&proteins&(28,29).& &Apoptotic&stimuli&cause&a&shift&in&the&ratio&between&the&proQ&and&antiQapoptotic&BclQ2& family&proteins,&allowing& for& the&oligomerization&of&Bax&and& Bak& and& the& formation& of& mitochondrial& pores& which& result& in& the& release& of&cytochrome&C&and&the&activation&of&caspaseQ3&via&caspaseQ9&(29,30).&The&IAP&family&consists&of&8&evolutionarily&conserved&members&originally&described&in& baculovirus,& including& cQIAP1,& cQIAP2,& and& the& XQlinked& inhibitor& of& apoptosis& (XIAP),&which&contain&at& least&one&Baculovirus&IAP&Repeat&(BIR)&domain&and&function&at&multiple&levels& in& the&apoptotic&cascade& to&prevent&cell&death& (31,32).& &For& instance,& cQIAP1&and&cQIAP2& proteins& inhibit& apoptosis& by& indirectly& suppressing& caspaseQ8& activation& (31,33).&&XIAP& is&able& to&regulate&apoptosis&by&binding&to&both&caspaseQ9&and&caspaseQ3&to&prevent&their&activation&(Fig.&14)&(31,34).&&In&addition,&XIAP&levels&have&been&found&to&be&elevated&in&numerous& cancers& and& have& recently& gained& interest& as& prognostic& markers& in& bladder,&colon,&and&renal&cancers&(35Q38).&Another&important&group&of&antiQapoptotic&regulators&is&the&Hsp&family.&&Hsps&are&a&large&family&of&conserved&chaperones&whose&expression&is&increased&by&cellular&stress&(e.g.&heat&and&cellular&toxins)&to&prevent&protein&aggregation&and&aid&in&refolding&(39).& &Family&members&are&classified&based&on&their&molecular&weight&and&are&divided&into&highQ&and&lowQ&molecular&weight&proteins.& &The&highQmolecular&weight&Hsps,&including&Hsp60&and&Hsp70,&
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require& ATP& to& mediate& protein& folding,& while& the& small& Hsps,& like& Hsp22& and& Hsp27,&interact&with&proteins& in&an&ATPQindependent&manner&(39,40).& &Small&Hsps&(sHsps)&share&several& structural& features& including& a& hydrophobic& NQterminal& that&mediates& chaperone&activity& and& contributes& to& oligomerization,& and& a& hydrophilic& CQterminal& that& contains& a&highly& conserved& αQcrystallin& domain& involved& in& proteinQprotein& interactions& (40,41).&&Monomers&of&sHsps&form&homodimers&in&an&antiQparallel&orientation&that&then&become&the&building& blocks& of& structurally& diverse& functional& oligomers& ranging& from& 50& to& 800& kDa&(40,42).& &Hsp27,&a&27&kDa&protein&of&205&aa,&has&emerged&as&an& important&antiQapoptotic&regulator&by&interfering&with&the&apoptotic&cascade&at&multiple&levels.& &The&Hsp27&protein&harbors& three&phosphorylation&sites&at&Ser15,&Ser78,& and&Ser82& that&have&been&shown& to&regulate& its& antiQapoptotic& activity& by& preventing& its& association& with& proQapoptotic&molecules&when&all&three&sites&are&phosphorylated&(43).&&The&phosphorylation&of&Hsp27&is&mediated&by&several&kinase&signaling&networks,&including&the&Protein&kinase&Cδ&(PKCδ)&and&the&MK2/p38&pathway&(44,45).& &The&NQterminal&(specifically&aa&51Q88)&of&Hsp27&has&been&shown&to&bind&to&cytochrome&C,&thereby&preventing&caspaseQ9&activation&(46).&&In&addition,&Hsp27& associates& directly& to& the& prodomain& of& caspaseQ3& inhibiting& the& autocatalytic&cleavage&necessary&for&its&activation&(Fig.&14)&(21).& &However,&the&specific&binding&domain&of&Hsp27&responsible&for&the&interaction&with&caspaseQ3&has&not&been&elucidated.&&
1.3!Flavonoids&& Flavonoids& are& plant& phytochemicals& that& are& considered& nonQessential& nutrients&that&provide&numerous&health&benefits.& &Compounds&with&bioactive&functions&that&provide&health&advantages&are&known&as&nutraceuticals.&&Nutraceuticals&include&soluble&fibers,&plant&
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sterols,& isothiocyanates,& phytoestrogens& (e.g.& lycopene,& resveratrol),& and& flavonoids& (47).&&There&are&more&than&5,000&flavonoids&that&can&be& further&subdivided&based&on&structural&differences& from& the& core& 2QphenylQ4HQchromenQ4Qone& (Flavone;& Fig.& 1A)& structure& into&flavones,&isoflavones,&flavonols,&flavanols,&flavonones,&and&anthocyanins&(47,48).&The& health& benefits& of& dietary& flavonoids& have& been& extensively& documented&through&numerous&studies&which&show&they&possess&antiQinflammatory,&antiQoxidant,& and&antiQtumorigenic&properties&(48).&&Research&has&shown&that&flavonoids&can&reduce&the&risk&of& Parkinson’s,& strokes,& and& cardiovascular& diseases& (49Q51).& & The& incidence& of& various&cancers,& including& breast,& ovarian,& colorectal,& and& lung,& have& been& shown& to& be& inversely&related& to& the& dietary& uptake& of& flavonoids& (52Q55).& & These& studies& demonstrate& why&flavonoids&have&attracted&attention& for& their&potential& therapeutic& capabilities.& &However,&epidemiological&studies&are&scarce&and&the&effectiveness&of&these&compounds&has&yet&to&be&fully&determined.&The&flavone&apigenin&(5,7,4’Qtrihydroxyflavone;&Fig.&1B)&can&be&found&in&a&variety&of&vegetables,&fruits,&and&chamomile&tea,&but&is&most&abundant&in&parsley&and&celery&(56Q58).&&Apigenin& has& antiQcarcinogenic,& antiQproliferative,& and& antiQinflammatory& properties& (59).&&The&bioactivity&of&apigenin&stems&from&its&ability&to&inhibit&proteins&like&BclQ2,&activate&proQapoptotic& proteins& like& PKCδ,& and& induce& DNA& damage,& which& subsequently& leads& to&apoptosis&(60Q62).& &We&recently&showed&that&apigenin&induces&apoptosis&in&leukemia&cells&(61).& & Apigenin& has& also& been& shown& to& cause& apoptosis& in& some& solid& tumors,& such& as&prostate& cancers& and& breast& cancers& that& express& the& HER2/neu& receptor& (63,64).&&However,&generally&apigenin&has&been&found&to&simply&inhibit&mobility,&tumor&invasion,&and&tumor&growth,&as&opposed&to&inducing&cell&death,&especially&in&lung&cancers&(65Q68).&&It&has&
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Figure 1. The structures of common flavonoids.  A: The core flavonoid structure, called “flavone,” 
showing the numbering system for the core flavonoid structure.  B: The flavone apigenin.  C: The 
flavone luteolin.  D: The flavonol quercetin.  E: The flavonol kaempferol.  F: The isoflavone genistein.  






2.1.1!! Clones!into!pENTR/DETOPO!Vector&FullQlength&caspaseQ3&(AB&249,&Table&1)&and&Hsp27&(AB&262,&Table&1)&were&used&as&template&DNA&in&PCR&reactions&to&generate&caspaseQ3&wt&FL&(AB&441,&PAO&369/355),&Hsp27&wt& FL& (AB& 374,& PAO& 356/357),& Hsp27& NQterminal& (AB& 827,& PAO& 356/565),& Hsp27& CQterminal&(AB&771,&PAO&564/357),&Hsp27&Δ187Q205&(AB&814,&PAO&356/559),&Hsp27&Δ154Q205&(AB&824,&PAO&356/560),&Hsp27&Δ137Q205&(AB&810,&PAO&356/561),&Hsp27&Δ120Q205&(AB&811,&PAO&356/562),&and&Hsp27&Δ104Q205&(AB&812,&PAO&356/563)&into&the&pENTR/DQTOPO& vector& (Invitrogen,& Carlsbad,& CA).& & Sequences& were& amplified& by& PCR& to& generate&clones&containing&the&restriction&enzyme&sites%BamHI&and&SalI&or&BamHI&and&XhoI&(Table&1).&&All&PCR&reactions&were&done&with&30&ng&of&template&DNA,&12.5&pmol&each&of& forward&and&reverse&primers& (Table&2),&50&μM&dNTP,&1&x&High&Fidelity&PCR&Buffer& (Invitrogen),&3&mM&MgCl2,&and&1&unit&High&Fidelity&Taq&Polymerase&(1&unit&=&incorporate&10&nmol&of&dNTP&into&DNA& in& 30&min& at& 74°C,& Invitrogen)& in& a& final& volume& of& 50& μl.& & The& PCR& reactions&were&carried&out&with&30&cycles&under&the&following&conditions:&1&min&at&95°C,&1&min&at&55°C,&and&1&min&at&75°C.&&Products&of&the&PCR&reactions&were&used&in&ligation&reactions&to&obtain&the&PCR&fragment&in&the&pENTR/DQTOPO&vector.& &For&this&purpose,&10&ng&of&PCR&product&was&mixed&with&10&ng&of&pENTR/DQTOPO&vector,&and&0.25&μl&salt&solution&(6&mM&NaCl,&0.3&mM&MgCl2)&at&room&temperature&for&30&min&in&a&final&volume&of&5&μl.& &Ligation&reactions&were&then&used&to&transform&E.%coli&TopQ10&cells&as&described&in&section&2.2&and&then&plated&on&
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LBQagar& (1%&(w/v)& tryptone,&0.5%&(w/v)&yeast&extract,&0.5%&(w/v)&NaCl)&with&30&µg/ml&kanamycin.&&
2.1.2! Generation!of!Hsp27!Clones!for!Mammalian!Expression&Hsp27& mutants& were& cloned& into& the& pCDNA3Q5& x& myc& mammalian& expression&vector.&&TOPOQHsp27&plasmids&were&digested&with&BamHI&and&XhoI&for&3&h&at&37°C,&run&on&a&1%& agarose& gel,& and& the& DNA& insert& was& excised& and& purified& from& the& gel& using& the&PureLink&Quick&Gel&Extraction&Kit& following& the&manufacturer’s& instructions& (Invitrogen).&&The&obtained&DNA&fragment&and&pCDNA3Q5&x&myc&vector&were&ligated&at&a&10:1&molar&ratio&with&400&units&of&T4Qligase& (New&England&Biolabs,& Ipswich,&MA)& in&1&x&T4Qligation&buffer&(50&mM&TrisQHCl,& 10&mM&MgCl2,& 10&mM&DTT,& 1&mM&ATP,& pH& 7.5;& New& England& Biolabs,&Ipswich,&MA)&and&distilled&water& in&a& total&volume&of&5&μl.& &The& ligation&was& incubated&at&16°C& for& 14& h& and& then& the& entire& reaction& was& used& to& transform& E.% coli% DH5α& cells&(Invitrogen)&and&plated&on&LBQagar&plates&with&100&μg/ml&ampicillin.&&Clones&were&screened&for&the&presence&of&the&correct&insert&by&digesting&with&BamHI&and&XhoI&for&3&h&at&37°C&and&running&on&a&1%&agarose&gel&as&described&in&section&2.2.&&
2.1.3! Generation!of!Clones!for!Bacterial!Expression&& CaspaseQ3&and&Hsp27&were&digested&from&the&pENTR/DQTOPO&vector&(AB&249&and&AB& 262,& respectively,& Table& 1)& using&BamHI& and& SalI& enzymes& and& purified& as& described&above.&&The&obtained&DNA&fragment&and&pQE31&or&pQE32&vector&(for&caspaseQ3&or&Hsp27,&respectively;&Qiagen,&Valencia,&CA)&were&ligated&at&a&10:1&molar&ratio&with&400&units&of&T4Qligase& in& 1& x& ligation&buffer& and&distilled&water& to& a& total& volume&of& 5& µl& for& 1& h& at& room&
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AB&Number Description Vector Primers Restriciton&Enzymes Bacterial&HostAB#249 Caspase,3#wt#FL pENTR/D,TOPO , BamHI/SalI DH5αAB#441 Caspase,3#wt#FL pQE31 PAO#369/355 BamHI/SalI DH5αAB#262 Hsp27#wt#FL pENTR/D,TOPO , BamHI/SalI DH5αAB#379 Hsp27#wt#FL pCDNA3,5x#myc PAO#356/357 BamHI/XhoI DH5αAB#381 Hsp27#N,terminal pCDNA3,5x#myc PAO#356/565 BamHI/XhoI DH5αAB#380 Hsp27#C,terminal pCDNA3,5x#myc PAO#564/357 BamHI/XhoI DH5αAB#374 Hsp27#wt#FL pQE32 PAO#356/357 BamHI/SalI DH5αAB#827 Hsp27#N,terminal pQE32 PAO#356/565 BamHI/SalI DH5αAB#771 Hsp27#C,terminal pQE32 PAO#564/357 BamHI/SalI DH5αAB#814 Hsp27#Δ187,205 pENTR/D,TOPO PAO#356/559 BamHI/XhoI Top,10AB#823 Hsp27#Δ187,205 pCDNA3,5x#myc PAO#356/559 BamHI/XhoI DH5αAB#824 Hsp27#Δ154,205 pENTR/D,TOPO PAO#356/560 BamHI/XhoI Top,10AB#815 Hsp27#Δ154,205 pCDNA3,5x#myc PAO#356/560 BamHI/XhoI DH5αAB#810 Hsp27#Δ137,205 pENTR/D,TOPO PAO#356/561 BamHI/XhoI Top,10AB#816 Hsp27#Δ137,205 pCDNA3,5x#myc PAO#356/561 BamHI/XhoI DH5αAB#811 Hsp27#Δ120,205 pENTR/D,TOPO PAO#356/562 BamHI/XhoI Top,10AB#817 Hsp27#Δ120,205 pCDNA3,5x#myc PAO#356/562 BamHI/XhoI DH5αAB#812 Hsp27#Δ104,205 pENTR/D,TOPO PAO#356/563 BamHI/XhoI Top,10AB#818 Hsp27#Δ104,205 pCDNA3,5x#myc PAO#356/563 BamHI/XhoI DH5α
Table&2
Primer&Number Sequence PurposePAO$355 3'(GAATTCGTCGACTTAGTGATAAAAATAGAG(3' RP$for$caspase(3$FL$into$pQE31PAO$356 5'(CACCGGGATCCAAGAATTCATGACCGAGCGCCGC(3' FP$for$Hsp27$into$pCDNA3(5x$myc$or$pQE32PAO$357 5'(GCTCGAGGTCGACCCCTTGGCGGCAGTCTCATC(3' RP$for$Hsp27$into$pCDNA3(5x$myc$or$pQE32PAO$369 5'(CACCGGATCCCCATGGAGAACACTGAAAACTC(3' FP$for$caspase(3$FL$into$pQE31PAO$559 5'(GCTCGAGGTCGACCCCTCGAAGGTGACTGGGAT(3' RP$for$Hsp27$Δ187(205$into$pCDNA3(5x$mycPAO$560 5'(GCTCGAGGTCGACCCAACTTGGGTGGGGTCCAC(3' RP$for$Hsp27$Δ154(205$into$pCDNA3(5x$mycPAO$561 5'(GCTGGAGGTCGACCCCCGGGAGATGTAGCCATG(3' RP$for$Hsp27$Δ137(205$into$pCDNA3(5x$mycPAO$562 5'(CACCGGGATCCAAGAATTCACCATCCCAGTCACCTTCGAGTC(3' RP$for$Hsp27$Δ120(205$into$pCDNA3(5x$mycPAO$563 5'(GCTCGAGGTCGACCCGTGGTTGACATCCAGGGA(3' RP$for$Hsp27$Δ104(205$into$pCDNA3(5x$mycPAO$564 5'(GCTCGAGGTCGACCCCGAGACCCCGCTGCTGAG(3' FP$for$Hsp27$C(terminal$into$pCDNA3(5x$myc$and$pQE32PAO$565 5'(CACCGGGATCCAAGAATTCGAGATCCGGCACACTGCG(3' RP$for$Hsp27$N(terminal$into$pCDNA3(5x$myc$and$pQE32
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2.2!! Transformation!of!E.#coli,!Bacterial!Culture,!and!DNA!Purification&PCR& and& ligation& products&were& used& to& transform& either&E.% coli& DH5α& or& TopQ10&bacterial& cells& (Invitrogen;& efficiency& >& 1& x& 106& cfu/μg& DNA& and& >& 1& x& 109& cfu/μg& DNA,&respectively).& &Briefly,& 25&μl& of& cells&were& incubated&with&1&μl& of&PCR&products&or&5&μl& of&ligation&products&for&30&min&on&ice.&&Cells&were&then&subjected&to&heat&shock&at&42°C&for&45&sec&followed&by&incubation&on&ice&for&2&min.&&Samples&were&then&given&250&μl&of&SOC&media&(2%&(w/v)&tryptone,&0.5%&(w/v)&yeast&extract,&8.6&mM&NaCl,&2.5&mM&KCl,&20&mM&MgSO4,&20&mM&glucose)& and& incubated& at& 37°C& for&1&h.& & Finally,& cells&were&plated&on&LBQagar&plates&with&the&appropriate&selective&antibiotic&and&allowed&to&grow&overnight&at&37°C.&For&bacterial&liquid&culture,&one&bacterial&colony&was&inoculated&into&a&14&ml&culture&tube&containing&3&ml&of&LB&broth&(1%&(w/v)&tryptone,&0.5%&(w/v)&yeast&extract,&0.5%&(w/v)&NaCl)&with&appropriate& antibiotics& and& the& culture&was&grown&at&37°C& for&16&h.& & Plasmid&DNA& was& purified& using& the& QIAprep& Miniprep& Spin& Kit& following& the& manufacturer’s&instructions&(Qiagen).&&The&purified&plasmid&DNA&was&digested&to&screen&for&positive&clones&using&0.5&μg&of&DNA&in&a&10&µl&reaction&with&1&x&BSA,&1&x&appropriate&NEBuffer&(Buffer&3:&100&mM&NaCl,&50&mM&TrisQHCl,&10&mM&MgCl2,&1&mM&DTT,&pH&7.9;&New&England&Biolabs),&5,000&units&of& each& restriction&enzyme& (Table&1),& and&distilled&water.& &The&digestion&was&performed& at& 37°C& for& 3& h.& & DNA& loading& buffer& 6& x& (0.25%&bromophenol& blue& and& 30%&glycerol&in&water)&was&added&to&the&digestion&product&to&reach&1&x&and&samples&were&run&on&a& 1%& agarose& gel& containing& 0.2& μg/ml& ethidium& bromide& in& TAE& Buffer& (40& mM& TrisQacetate,&1&mM&EDTA,&pH&8.0)&using&the&1&Kb&plus&DNA&ladder&(Invitrogen)&to&verify&the&size&of&the&digested&fragments.& &The&gel&was&run&for&30&min&at&100&V&and&DNA&fragments&were&cut&and&purified&using&the&PureLink&Quick&Gel&Extraction&Kit&as&described&in&section&2.1.2.&
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2.3! Cell!Tissue!Culture&HeLa&(human&cervical&cancer),&H9c2&(rat&cardiomyocyte),&A549&(Stage&I& lung&ACC),&H2009&(Stage&IV&lung&ACC),&and&H1299&(lung&LCC)&cells&obtained&from&the&American&Type&Culture&Collection&(ATCC)&and&CaluQ1&(Stage&III& lung&SCC)&cells&generously&donated&by&Dr.&Croce& (Ohio& State& University),& were& grown& at& 37°C& in& an& atmosphere& of& 5%& CO2.& & HeLa,&H9c2,& A549,& H2009,& and&H1299& cells&were& cultured& in& high& glucose& Dulbecco’s&modified&Eagle’s&medium&(DMEM;&Life&Technologies,&Grand&Island,&NY)&supplemented&with&5%&fetal&bovine& serum& (FBS)& and& 1%& penicillin& and& streptomycin& solution& (P/S;& BioWhittaker,&Walkersville,& MD),& while& CaluQ1& cells& were& grown& in& Rosewell& Park& Memorial& Institute&medium& (RPMI)& with& 10%& FBS& and& 1%& P/S.& & H9c2& cells& were& treated& with& 10& μM&doxorubicin& (dox;&SigmaQAldrich,&St.&Louis,&MO)& for&12&h& to& induce&apoptosis.& &NSCLC&cell&lines& (A549,& H2009,& H1299,& and& CaluQ1)& were& treated& with& various& concentrations& of&apigenin& (SigmaQAldrich),& ranging& from& 1& to& 50& µM,& and/or& human& recombinant& TRAIL&(EMD&Millipore,&Billerica,&MA),&ranging&from&25&to&100&ng/ml.&&
2.4!! Cell!Viability!Assays!
! Cell& viability& was& determined& using& the& CellTiter& 96®& Aqueous& One& Solution& Cell&Proliferation&Assay&(MTS;&Promega,&Madison,&WI).&&Cells&were&seeded&in&a&96Qwell&plate&at&a&density&of&8,000&cells/75&μl&media/well.&&Twelve&hours&later,&cells&were&treated&with&1,&10,&25,&and&50&μM&apigenin&or&DMSOQdiluent&control&for&24&h.&&Next,&25,&50,&or&100&ng/ml&TRAIL&or&TRAIL&Buffer&alone&was&added&and&cells&were&cultured&for&an&additional&24&h.&&The&MTS&
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reagent& was& added& and& cells& were& incubated& for& 2& h& at& 37°C& before& measuring& the&absorbance&at&490&nm&on&a&multiQplate&reader&VICTOR™&X3&(Perkin&Elmer,&Waltham,&MA).&&
2.5! Flow!Cytometry!
! The&percentage&of!apoptosis&was&analyzed&using&the&Annexin&V&Apoptosis&Detection&Kit&(BD&Biosciences,&San&Jose,&CA).&&Briefly,&2.5&x&105&cells&were&stained&in&0.1&ml&of&Annexin&V&binding&buffer&containing&1%&FBS,&1&μg&Annexin&VQAPC,&0.5&μg&7QAAD&for&20&min&on&ice.&&Cells&were&rinsed&with&0.5&ml&of&Annexin&V&staining&buffer&and&centrifuged&at&1,200&rpm&at&4°C& for& 5& min.& Cell& pellets& were& resuspended& in& 0.1& ml& of& Cytofix/CytopermTM& (BD&Biosciences,& San& Jose,& CA),& incubated& for&20&min&on& ice,&washed& twice&with&0.5&ml& of& the&Annexin& V& staining& buffer,& and& spun& at& 1,200& rpm& at& 4°C& for& 5& min.& & Pellets& were&resuspended&with& 0.1&ml& of& permeabilization& solution& containing& either& 1& μg& of& antiQIgG&isotype&controlQFITC&or&antiQactiveQcaspaseQ3QFITC&antibodies.&&Cells&were&rinsed&twice&with&0.5&ml&in&Annexin&V&staining&buffer,&spun&at&1,200&rpm&at&4°C&for&5&min,&and&resuspended&in&0.5&ml&of&Annexin&V&staining&buffer&containing&1%&paraformaldehyde.&&Samples&were&then&analyzed&by&flow&cytometry.&&
2.6! !Transient!Transfection&Eight&million&HeLa&or&H9c2&cells&in&5&ml&of&media&were&transiently&transfected&with&8&µg&of&DNA&using&15&µl&of&Lipofectamine&2000&(Invitrogen)&and&incubated&for&4&h&at&37°C&in&5&ml& of& serumQfree&DMEM.& & Following& incubation,& 5&ml& of&DMEM& containing& 20%&FBS&was&added&and&cells&were&cultured&for&an&additional&8&h.&&TwentyQfour&hours&after&transfection&samples& were& collected& by& detaching& cells& using& 0.05%& TrypsinQEDTA& (Invitrogen,&
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Carlsbad,&CA)&for&5&min&at&37°C,&transferred&to&Falcon&tubes,&and&centrifuged&at&1,200&rpm&for& 5& min.& & Cells& were& washed& with& 0.5& ml& PBS,& transferred& to& an& eppendorf& tube,& and&centrifuged&at&6,000&rpm&for&5&min&at&4°C.&&Cell&pellets&were&snapQfrozen&in&liquid&nitrogen&and&stored&at&Q80°C.&&
2.7!! Western!Blot!Analysis!HeLa& lysates&were&prepared&by&resuspending&cell&pellets& in&Lysis&Buffer&B&(50&mM&HEPES&pH&7.5,& 2.5&mM&EGTA,&1&mM&EDTA,&150&mM&NaCl,& 10%&glycerol,& 0.1%&TweenQ20&containing&50&mM&NaF,&10&mM&NaQglycerophosphate,&5&mM&NaQpyrophosphate,&1&mM&NaQorthovanadate,& 1&mM& DTT,& 1&mM& PMSF,& and& 2& μg/mL& protease& inhibitors:& chymostatin,&leupeptin,&antipain,&and&pepstatin).&&H9c2&and&NSCLC&cell&lysates&were&resuspended&in&NPQ40&lysis&buffer&(10&mM&TrisQCl,&pH&7.5,&0.5%&(v/v)&NPQ40,&1&mM&DTT,&0.1&mM&PMSF,&2&μg/ml&protease&inhibitors)&for&1&h&at&4°C&under&constant&vortexing.&&Lysates&were&centrifuged&for&5&min&at&13,200&rpm&at&4°C&and&supernatants&were&stored&at& Q80°C.& &Protein&concentration&was&determined&by&mixing&1&μl&of&lysate&with&199&μl&of&1&x&Bradford&Protein&Assay&reagent&(BioQRad,&Hercules,&CA)&for&5&min&at&room&temperature.&&Absorbance&was&measured&at&595&nm&and&protein&concentration&was&calculated&using&a&standard&curve&of&0,&1,&2,&4,&6,&8,&and&10&μg&BSA.& &Samples&were&measured&on&a&96Qwell&plate&using&the&multi& label&plate&reader&VICTOR™&X3&(Perkin&Elmer).&Equal&amounts&of&protein&were&heated&at&95°C&for&5&min&in&SDS&loading&buffer&(250&mM& Tris,& pH& 6.8,& 10%& SDS,& 50%& glycerol,& 0.5%& bromophenol& blue,& and& 1.78& M& 2Qmercaptoethanol).& & Protein& samples,& along& with& the& SeeBlue®& Plus& Marker& (Invitrogen),&were&resolved&by&SDSQPAGE&on&a&12%&gel&by&running&at&100&V&for&10&min&followed&by&160&V&
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Antibody Clone Type Catalog&Number Company Locationanti%caspase%3 19 monoclonal 610323 BD5Biosciences San5Jose,5CAanti%active%caspase%3%FITC % monoclonal 559341 BD5Biosciences San5Jose,5CAanti%Bid FL%195 polyclonal SC11423 Santa5Cruz Santa5Cruz,5CAanti%DR5 % polyclonal AB16942 Millipore Billerica,5MAanti%GAPDH FL%355 polyclonal SC25778 Santa5Cruz Santa5Cruz,5CAanti%Hsp27 % polyclonal SPA803 Assay5Designs Ann5Arbor,5MIanti%Hsp70 C92F3A%5 monoclonal SPA810 Assay5Designs Ann5Arbor,5MIanti%IgG % monoclonal SC2025 Santa5Cruz Santa5Cruz,5CAanti%IgG % polyclonal SC2027 Santa5Cruz Santa5Cruz,5CAanti%IgG%FITC % polyclonal 555786 BD5Biosciences Billerica,5MAanti%IgG%PE G18%145 polyclonal 555787 BD5Biosciences Billerica,5MAanti%myc 9E10 monoclonal SC40 Santa5Cruz Santa5Cruz,5CAanti%XIAP 28 monoclonal 610717 BD5Biosciences San5Jose,5CAanti%β%Tubulin AA2 monoclonal SC80011 Santa5Cruz Santa5Cruz,5CAanti%mouse%HRP % monoclonal NA931V GE5Healthcare Buckinghamshire,5UKanti%rabbit%HRP % polyclonal NA934V GE5Healthcare Buckinghamshire,5UK
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2.8! Immunoprecipitation&For&immunoprecipitations&(IP)&of&mycQtagged&Hsp27&chimera&proteins,&5&x&106&HeLa&cells,&transiently&transfected&as&described&in&section&2.8&were&lysed&in&Lysis&Buffer&B&for&1&h&at& 4°C.& & One& milligram& of& cell& lysate& was& immunoprecipitated& using& 1& µg& of& antiQmyc&antibodies&or&antiQIgG&isotype&control&antibodies&(Table&3),&in&a&total&volume&of&0.5&ml,&and&incubated& in& a& 360°& rotator& overnight& at& 4°C.& & The& IPs& were& then& incubated& with& 30& μl&Protein& GQAgarose& beads& (Invitrogen,& Carlsbad,& CA)& for& 1& h& at& 4°C.& & The& mixtures& were&washed&four&times&with&500&μl&of&Lysis&Buffer&B.&&IPs&were&resuspended&in&20&μl&of&2&x&SDS&loading& buffer& and& heated& at& 95°C& for& 5& min.& & Western& Blot& analysis& was& performed& as&described&in&section&2.7.&For&immunoprecipitations&of&endogenous&DR5,&5&x&106&of&NSCLC&cells&were&lysed&in&1&ml&of&ice&cold&1%&NPQ40&buffer&(10&mM&TrisQCl,&pH&7.5,&1%&(v/v)&NPQ40,&1&mM&DTT,&0.1&mM&PMSF,&2&μg/ml&protease&inhibitors)&for&2&h&at&4°C.& &One&milligram&of&cell&extracts&was&immunoprecipitated& in& a& total& volume&of&0.5&ml&using&1&μg&of& antiQIgG& isotype& control& or&antiQDR5&antibodies&(Table&3).&&Reactions&were&incubated&for&14&h&at&4°C&and&mixed&with&30&μl&of&Protein&GQAgarose&beads.&&IPs&were&incubated&for&1&h&at&4°C,&rinsed&four&times&with&0.7&ml&of&1%&NPQ40&buffer,&and&resuspended&in&30&μl&of&2&x&SDS&loading&buffer&and&heated&at&95°C&for&5&min.&&Western&Blot&analysis&was&performed&as&described&in&section&2.7.&&
2.9! Caspase!Activity!Assays!CaspaseQ3,& Q8,& and& Q9&activity&was&determined&using& the& fluorescent& substrates&AcQAspQGluQValQAspQAFC& (DEVDQAFC),& AcQIleQGluQThrQAspQAFC& (IETDQAFC),& and& AcQLeuQGluQ
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HisQAspQAFC&(LEHDQAFC),&respectively&(Enzo&Life&Sciences,&Farmingdale,&NY).& &Cell& lysates&were&incubated&in&the&appropriate&reaction&buffer&(caspaseQ3&buffer:&10%&glycerol,&50&mM&PIPES,&pH&7.0,&1&mM&EDTA,&1&mM&DTT,&20&μM&DEVDQAFC;&caspaseQ8&buffer:&100&mM&HEPES,&pH&7.5,&10%&(w/v)& sucrose,&1&mM&EDTA,&1&mM&DTT,&20&µM& IETDQAFC;& caspaseQ9&buffer:&100&mM&MES,&pH&6.5,&10%&(w/v)&PEG,&0.1%&(w/v)&CHAPS,&1&mM&DTT,&20&µM&LEHDQAFC).&&The&release&of&free&AFC&was&measured&using&a&Cytofluor&4000&fluoromter&(Perspective&Co.,&Farmingham,&MA;&excitation&400&nm,&emission&508&nm).& &For&each&reaction,&20&μg&of& cell&lysates&were&mixed&with&reaction&buffer&to&a&total&of&200&μl&and&fluorometer&measurements&were&taken&every&30&sec&for&1&h.&&
2.10!Protein!Purification!
2.10.1!Purification!of!Hsp27&& An&individual&bacteria&colony&containing&pQE32QHsp27&plasmid&DNA&(AB&374,&Table&1)&was& grown& in& Terrific& Broth& (2.4%& yeast& extract,& 1.2%& tryptone,& 4%& glycerol,& 0.17&M&KH2PO4,&0.72&M&K2HPO4)&to&an&OD600&of&approximately&0.5.&&Protein&expression&was&induced&with&1&mM&IPTG& for&3&h&at&37°C.& &Cells&were&collected&and&2&g&of& the&bacterial&pellet&was&resuspended& in&20&ml&denaturing&buffer& (100&mM&NaH2PO4,&pH&8.0,&10&mM&Tris&and&8&M&urea)&and&incubated&for&30&min&at&room&temperature.&&Cells&were&sonicated&(output:&8,&duty&cycle:& 80,& utilizing& the& Sonifier& 450,& Branson&Ultrasonics,& Danbury,& CT)& and& lysates&were&incubated&with&250&μl&of&Ni2+QNTA&beads&(Qiagen)&for&90&min&at&room&temperature&in&the&presence&of&1&µl/mL&RNase&and&DNase.&&The&lysateQbead&mixture&was&loaded&onto&an&empty&column& and& the& flowQthrough& was& collected.& & The& beads& were& washed& twice& with& 5& ml&Buffer& C& (100&mM&NaH2PO4,& 10&mM&Tris,& 8&M& urea,& 1& μl/mL&RNase& and&DNase,& pH& 6.3).&&
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Elutions&were& collected&with& 5&ml&Buffer&D& (100&mM&NaH2PO4,& 10&mM&Tris,& 8&M&urea,& 1&μl/mL&RNase&and&DNase,&pH&5.9)&and&5&ml&Buffer&E&(100&mM&NaH2PO4,&10&mM&Tris,&8&M&urea,&1&μl/mL&RNase&and&DNase,&pH&4.5),&and&elution&fractions&containing&Hsp27&proteins&were& identified& by& SDSQPAGE& and& staining& with& Coomassie& solution& (0.25%& (w/v)&Coomassie& brilliant& blue& RQ250,& 50%& (w/v)& methanol,& 10%& (v/v)& glacial& acetic& acid)& at&room& temperature.& & The& denatured& proteins& were& refolded& by& a& stepwise& dialyzing&procedure,&first&for&3&h&at&room&temperature&in&dialysis&buffer&1&(25&mM&NaH2PO4,&100&mM&NaCl,&1%&glycerol,&0.1&mM&PMSF)&with&the&ratio&of&1&ml&protein&to&1000&ml&dialysis&buffer&1.&&Next,& protein& samples& were& dialyzed& for& 12& h& at& 4°C& in& dialysis& buffer& 1& with& the& same&protein:buffer&ratio.& &Precipitated&proteins&were&removed&by&centrifugation& for&10&min&at&4,000&rpm&and&supernatants&were&then&dialyzed&for&12&h&at&4°C&in&dialysis&buffer&2&(20&mM&Tris,& pH& 7.4,& 10& mM& NaCl,& 1& mM& EDTA,& 1& mM& DTT,& 0.1& mM& PMSF)& using& the& same&protein:buffer& ratio.& & Protein& yield& was& determined& by& Bradford& assay,& as& described& in&section&2.7.&&
2.10.2!Purification!of!CaspaseE3!& An& individual& bacteria& colony& containing& pQE31QcaspaseQ3& plasmid& DNA& (AB& 441,&Table&1)&was&grown&in&Terrific&Broth&to&an&OD600&of&approximately&0.5.&&Protein&expression&was& induced& with& 1& mM& IPTG& for& 30& min& at& 20°C.& & Cells& were& collected& and& lysed& via&sonication&(output:&8,&duty&cycle:&80,&utilizing&the&Sonifier&450)&in&sonication&buffer&(50&mM&sodium& phosphate,& pH& 7.8,& 300& mM& NaCl,& 5& mM& 2Qmercaptoethanol,& 1%& TweenQ20,& 2&µg/mL&protease&inhibitors,&and&1&mM&PMSF).&&Lysates&were&centrifuged&at&12,000&rpm&for&10&min&and&the&supernatants&were&treated&with&10&µg/ml&RNase&and&5&µg/ml&DNase&for&10&
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min&at&4°C.& &Supernatants&were& incubated&with&125&μl&of&Ni2+QNTA&beads&(Qiagen)& for&90&min& at& 4°C.& & The& lysateQbead& mixture& was& loaded& onto& an& empty& column& and& the& flowQthrough&was&collected.&&The&beads&were&washed&once&with&10&ml&of&washing&buffer&(50&mM&HEPES,&pH&7.4,&50&mM&NaCl,&10%&glycerol,&1%&TweenQ20,&0.1&mM&PMSF,&2&µg/ml&protease&inhibitors).&&Elutions&were&collected&in&washing&buffer&with&concentrations&of&imidazole&of&30,&50,&and&100&mM,&and&elution&fractions&containing&caspaseQ3&proteins&were&identified&by&SDSQPAGE& and& gels&were& stained&with& Coomassie& staining& as& described& in& section& 2.10.1.&&Fractions& containing& caspaseQ3&were&dialyzed& twice& in& caspaseQ3& reaction&buffer& (50&mM&HEPES,&pH&7.4,&50&mM&NaCl,&10%&(w/v)&sucrose,&1&mM&DTT,&0.1&mM&PMSF)&for&3&h&at&4°C&with&1&ml&of&protein&for&1000&ml&of&buffer.&&Protein&yield&was&determined&by&Bradford&assay,&as&described&in&section&2.7.&&
2.11!Structural!Modeling!& The& Swiss& Model& program& (http://swissmodel.expasy.org)& was& used& to& generate&Hsp27&models& based& on& sequence& homology&with& crystallized& proteins& submitted& to& the&Protein& Data& Bank& (PDB).& & Oligomeric& structures& were& built& by& modeling& Swiss& Model&structures& on& fully& crystallized& sHsps& and& aa& accessibility&was& calculated& using& the&Deep&View&program&(http://spdbv.vitalQit.ch,&version&4.04).&&The&accessibility&scale&included&with&each&figure&is&approximate&and&ranges&from&a&completely&buried&aa&(dark&blue)&to&an&aa&that&is&at&least&65%&accessible&(red).&&&&
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2.12!Isobolograms!
! Isobolograms&were& generated& from&NSCLC& combination& treatments& by& calculating&the& IC50& of& each& treatment& alone& to& graph& the& line&of& additivity.& & Combination& treatments&were& graphed& as& points& on& the& plots,& along& with& the& calculated& Combination& Index& (CI)&using&the&following&formula:&
&Where&(IC50)A& is& the&concentration&of&drug&A&alone&needed& for&a&50%&effect,& (IC50)B& is& the&concentration& of& drug& B& alone& needed& for& a& 50%& effect,& and& DA& and& DB& are& the&concentrations&of&drug&A&and&B&used&in&the&combination&treatment&for&a&50%&effect.&&
2.13!Statistical!Analysis!














3.1!Introduction!& Various&chemotherapy&drugs&have&been&shown& to& induce&apoptosis& in&cancer&cells&through& the& intrinsic& pathway& involving& mitochondrial& release& of& cytochrome& C& and&activation& of& caspaseQ9& (23,73Q75).& & Included& in& this& group& are& the& anthracyclines,&tetracyclic& compounds& originally& isolated& from& the& GramQnegative& bacteria& Streptomyces%
peuceticus,%and&considered&to&be&some&of&the&most&effective&chemotherapeutic&agents,&used&in& the& treatment& of& many& cancers& including& breast& cancers,& soft& tissue& sarcomas,&lymphomas,&and&acute&lymphoblastic&and&myeloblastic&leukemia&(Fig.&2)&(76Q81).&&However,&adverse&cytotoxic&effects&are&associated&with&these&drugs&(82).& &Doxorubicin&(dox),&one&of&the& most& commonly& used& anthracyclines,& functions& by& intercalating& DNA& and& inducing&apoptosis& caused& by& promoting& DNA& damage& (Fig.& 2A)& (76).& & The& anthracyclines&danorubicin,&epirubicin,&and&idarubicin&function&similarly,&but&have&been&shown&to&be&less&effective&than&dox&(Fig.&2B,&C,&and&D)&(76).& &However,&anthracyclines,& including&dox,&cause&dilated& cardiomyopathy& (weakening& and& enlarging& of& the& heart& muscle)& and& congestive&heart& failure& in& 30%& of& patients& with& a& mortality& rate& of& 30Q50%& (76).& & Cardiovascular&diseases&resulting&from&the&treatment&with&dox&are&caused&by&cardiomyocyte&death,&which&is& the&result&of&doxQinduced&ROS&production& that& leads& to& the& initiation&of&apoptosis&(22).&&However,& the& mechanisms& that& regulate& doxQmediated& cardiomyocyte& apoptosis& remain&unclear.& & Due& to& the& high& mortality& rate,& identifying& novel& approaches& to& reduce& the&cardiotoxicity&of&dox&treatment&is&of&great&importance.&
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& Hsp27& has& emerged& as& an& inhibitor& of& apoptosis& by& preventing& the&mitochondrial&release& of& cytochrome& C& and& inhibiting& caspaseQ3& activity& (21,46).& & OverQexpression& of&Hsp27&has&been&detected&in&many&cancer&cells&and&human&cancer&biopsies,&and&it&has&been&suggested& to& be& a& useful& prognostic& marker& (2,83,84).& & In& addition,& Hsp27& has& been&suggested& to& act& as& a& key& inhibitor&of& apoptosis& in& the& rat& cell& line&H9c2,& a&wellQaccepted&model& to& study& cardiomyocyte& biology& (85Q87).& & The& H9c2& cell& line& is& derived& from&embryonic& rat& hearts& and& retains&many& features& of& cardiac&muscle& including& the& cardiac&isoform& of& creatine& phosphokinase,& LQtype& Ca2+& channels,& and& the& tissueQspecific& splicing&protein&survival&of&motor&neuron&(SmN),&and&is&therefore&a&commonly&used&model&system&to&study&cardiomyocyte& life& span& (88,89).& & It&has&been&shown& that& increased& temperature&induces&Hsp27&expression&in&H9c2&cells,&and&this&increased&expression&is&able&to&block&doxQinduced&apoptosis& (82).& & Studies& further&demonstrated& that& chemotherapy&drugs,& such&as&cisplatin& or& gemcitabine,& can& increase& Hsp27& expression,& thereby& conferring& greater&chemoQresistance&(90).&&Our&group&previously&showed&that&Hsp27&associates&with&caspaseQ3& in& cells& of& the& immune& system& preventing& its& activation& during& apoptosis& (21).& & It& is&hypothesized& that& many& proteinQprotein& interactions& are& mediated& by& the& αQcrystallin&domain&of&Hsp27&(Fig.&3A).& &However,&the&mechanism&by&which&Hsp27&controls&caspaseQ3&and&its&role&in&the&inhibition&of&doxQinduced&apoptosis&has&not&been&characterized.&& In&this&study,&the&Hsp27&peptide&region&responsible&for&the&association&with&caspaseQ3&was& identified&and&shown&to&be&capable&of& inhibiting&apoptosis.& &Hsp27&nested&deletion&clones&were&generated&by&PCR&and&cloned&into&mammalian&expression&vectors.&&The&clones&were&subsequently&expressed&in&cells&and&it&was&determined&which&clones&were&unable&to&bind& to&caspaseQ3&by& immunoprecipitations.& &Our&results&showed&that& two&subdomains&of&
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Hsp27&between&aa&104Q119&and&154Q186&seem&to&contribute&to&the&binding&to&caspaseQ3.&&In&parallel,&proteinQmodeling&software&was&utilized&to&generate&an&Hsp27&structure&based&on&the& evolutionarily& related& archaean& Hsp16.5& (91).& & The& Hsp16.5& structure& was& used& to&obtain&an&Hsp27&model,&since&the&Hsp27&crystal&structure&has&not&yet&been&resolved,&to&aid&in&the&explanation&of&how&the&deletions&are&likely&involved&in&the&interaction&with&caspaseQ3.&&Finally,&our&studies&further&showed&that&a&loss&of&Hsp27&binding&to&caspaseQ3&resulted&in&decreased&protection&from&doxQinduced&apoptosis.&&
3.2!Identification!of!the!Hsp27!Peptide!Region!Responsible!for!the!Association!with!
CaspaseE3!
! To&determine&the&Hsp27&region&that&is&directly&involved&in&the&association&with&and&inhibition& of& caspaseQ3,& several& Hsp27& clones& lacking& specific& domains& were& generated.&&Initially,&NQterminal&mycQtagged&clones&of& the& fullQlength&Hsp27&wt& (Hsp27QFL),&Hsp27&NQterminal,&and&Hsp27&CQterminal&were&cloned&into&a&mammalian&expression&vector&(Tables&1&and&2;&Fig.&3B).& &For& this&purpose,& the&Hsp27QFL&clone&(AB&262,&Table&1&and&Fig.&5A)&was&used&as&a&template&to&generate&Hsp27&NQterminal&using&the&primers&PAO&356&and&565&and&Hsp27& CQterminal& using& PAO& 564& and& 357& (Tables& 1& and& 2).& & The& obtained& Hsp27& DNA&fragments& were& cloned& into& the& BamHI/XhoI& sites& of& the& pCDNA3Q5& x& myc& mammalian&expression&vector,&which&carries&an&NQterminal&mycQepitope&tag&and&allows&for&expression&in&mammalian&cells.&&&The&clones&were&transiently&transfected&in&HeLa&cells&and&cell& lysates&were&used&in&western& blot& analyses& to& determine& that& the& clones&were& expressed& at& similar& levels& and&that& the&proteins&were&of& the&proper& size& (Fig.& 3B,& Input).& & To& study& the& association&with&
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caspaseQ3,&the&lysates&were&immunoprecipitated&(IP)&with&antiQcaspaseQ3&antibodies&or&an&antiQIgG&isotype&control&(Fig.&3B,&lane&1).&&The&IPs&were&resolved&by&SDSQPAGE,&transferred&to&nitrocellulose,& and&proteins&were&detected&by& immunoblotting&with&antiQmyc&and&antiQcaspaseQ3& antibodies& (Fig.& 3B).& &Our& results& showed& that& the&Hsp27QFL&and& the&Hsp27&CQterminal& were& able& to& bind& to& caspaseQ3& (Fig.& 3B,& lanes& 3& and& 4),& while& the& Hsp27& NQterminal&was&not&able&to&associate&with&caspaseQ3&(Fig.&3B,&lane&2),&even&though&all&clones&were&expressed&at&similar&levels&as&shown&by&the&input&(Fig.&3B,&lanes&5Q7).& &These&results&suggest&that&the&CQterminal&domain&of&Hsp27&is&sufficient&to&bind&to&caspaseQ3.&&&To& determine& whether& the& Hsp27& CQterminal& domain& is& likewise& able& to& regulate&caspaseQ3& activity,& we& performed& caspase& activity& assays& using& purified& human&recombinant& 6& x& HisQtagged& Hsp27& proteins& containing& different& domains:& rHsp27QFL,&rHsp27&CQterm,&and&rHsp27&NQterm&(Fig.&3C).&&Hsp27&proteins&were&obtained&by&cloning&the&Hsp27&DNA&fragment&of& interest& into& the&pQE32&bacterial&expression&vector&and&proteins&were& purified& from& E.% coli& lysates& as& described& in& section& 2.10.1.& & Recombinant& human&caspaseQ3&(rCaspQ3)&was&incubated&with&the&rHsp27&proteins&and&the&complex&was&allowed&to& form& for& 30&min& at& 4°C.& & Next,& recombinant& activeQcaspaseQ9& (rCaspQ9)& was& added& to&induce&the&activation&of&caspaseQ3&for&up&to&2&h&at&37°C.&&CaspaseQ3&activity&was&determined&by&following&the&release&of&fluorescence&upon&the&cleavage&of&the&DEVDQAFC&substrate&(Fig.&3C).& & The& rHsp27QFL& and& rHsp27& CQterm& domains& were& both& able& to& inhibit& caspaseQ3&activity&at&a&similar&level,&while&rHsp27&NQterm&was&unable&to&prevent&its&activity&at&a&level&similar& to&that&observed& in&the&absence&of&Hsp27&(Fig.&3C).& & In&addition,& the&processing&of&caspaseQ3&was& followed& by&western& blot& analyses& using& antiQcaspaseQ3& antibodies,&which&recognize&an&epitope&on&the&p17&subunit&of&caspaseQ3&to&distinguish&the&precursor&(inactive&
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enzyme)&as&well& as& smaller& subunits& (prop17&and&p17)& that&present&when& the&enzyme& is&active& (Table& 3;& Fig.& 3D).& & Similar& to& the& activity& assay,& after& 2& h& of& incubation& the&immunoblots&showed&that&rHsp27&NQterm&allows&for&caspaseQ3&proteolytic&processing&and&formation&of& the& free&p17&subunit,&while&rHsp27QFL&and&rHsp27&CQterm& inhibit&caspaseQ3&activation&at&the&autocatalytic&cleavage&of&the&prodomain&(Fig.&3D).&& Based&on&our&previous& results,& it&was&hypothesized& that& the&Hsp27&peptide& region&responsible&for&the&association&with&caspaseQ3&is&located&within&the&CQterminal&domain.&&To&define& a& smaller& peptide& region& capable& of& inhibiting& the& association&with& and& activity& of&caspaseQ3,&a&series&of&mycQtagged&Hsp27&nested&deletion&clones&were&generated&(Fig.&5A).&&The& size& of& each& successive& deletion&was& based& on& the& conserved& secondary& structure& of&several& evolutionarily& related& Hsp27& proteins& from& various& species& with& deletions&occurring& adjacent& to& whole& βQsheets& or& αQhelices& (Fig.& 4).& & Five& deletion& clones& were&generated& that& encode& for& Hsp27& Δ187Q205& and& deletion& of& the& CQterminal& extension,&Hsp27&Δ154Q205&and&deletion&of&β8&and&β9,&Hsp27&Δ137Q205&and&deletion&of&β7&and&α2,&Hsp27&Δ120Q205&and&deletion&of&β5&and&α1,&and&Hsp27&Δ104Q205&and&deletion&of&β4&(Fig.&4).& &The&Hsp27QFL&clone&(AB&262,&Table&1)&was&used&as&a&template&to&generate&the&Hsp27&nested& deletion& clones& by& PCR.& & The& primers& PAO& 356& and& 559& were& used& to& generate&Hsp27& Δ187Q205,& PAO& 356& and& 560& for& Hsp27& Δ154Q205,& PAO& 356& and& 561& for& Hsp27&Δ137Q205,&PAO&356&and&562&for&Hsp27&Δ120Q205,&and&PAO&356&and&563&for&Hsp27&Δ104Q205&(Tables&1&and&2).&&The&PCR&products&were&run&on&agarose&gels&and&were&found&to&be&of&the&expected&558&bp&for&Hsp27&Δ187Q205,&459&bp&for&Hsp27&Δ154Q205,&408&bp&for&Hsp27&Δ137Q205,&357&bp& for&Hsp27&Δ120Q205,&and&309&bp& for&Hsp27&Δ104Q205&(Fig.&5B).& &After&sequencing& the& PCR& products& to& ensure& accuracy& of& the&mutant,& the& Hsp27& inserts&were&
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subcloned&into&the&mycQtagged&mammalian&expression&vector.&&Samples&were&screened&for&the&presence&of&the&insert&using&restriction&enzyme&analysis&with&BamHI&and&XhoI,&and&the&same&expected&insert&sizes&as&described&above&as&well&as&the&mycQvector&of&5500&bp&were&obtained&&(Fig.&5C).&&&& To&determine&the&subdomain&of&Hsp27&required&for&the&association&with&caspaseQ3,&the&obtained&mycQtagged&Hsp27&deletion&clones&were&transiently&transfected&in&HeLa&cells.&&Western&blot&analyses&with&antiQmyc&antibodies&showed&equal&expression&of&proteins&of&the&proper&size&were&obtained&(Fig.&6,&Input).&&To&determine&the&subdomain&of&Hsp27&required&for&the&association&with&caspaseQ3,&the&lysates&were&immunoprecipitated&(IP)&with&antiQmyc&antibodies&or&an&antiQIgG& isotype& control& (Fig.&6,& lane&1).& &The& IPs&were& resolved&by&SDSQPAGE& and& proteins& were& detected& by& immunoblotting& with& antiQmyc& and& antiQcaspaseQ3&antibodies& (Fig.& 6,& lanes& 1Q9).& & & Hsp27& Δ187Q205& was& able& to& associate& with& caspaseQ3&similar& to& Hsp27QFL& (Fig.& 6,& lanes& 2& and& 3).& & The& deletion& of& Hsp27& Δ154Q205& (clone& C)&showed& a& decrease& of& binding& to& caspaseQ3& of& about& 50%,& levels& similar& to& lysates&expressing&the&deletions&Hsp27&Δ136Q205&and&Hsp27&Δ120Q205,&corresponding&to&clones&D&and&E,&respectively&(Fig.&6,&lanes&4Q6).&&Binding&to&caspaseQ3&was&completely&abolished&when&Hsp27&aa&104Q119&were&deleted&(clone&F)&(Fig.&6,&lane&7).&&Collectively,&these&results&suggest&that&aa&154Q186&and&aa&104Q119&contribute&to&the&association&with&caspaseQ3.&&
3.3!The!Role!of!Hsp27!in!the!Regulation!of!CaspaseE3!in!Cardiomyocytes!& To& investigate& the& amino& acids& of& Hsp27& that& regulate& the& activity& of& caspaseQ3&during&apoptosis,& the&H9c2&cell& line&was&used&as&a&cardiomyocyte&model&(Fig.&7E).& &H9c2s&were& transiently& transfected& with& the& Hsp27& nested& deletion& clones,& and& 16& h& after&
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transfection,&apoptosis&was&induced&by&treating&with&10&µM&dox&for&12&h.&&The&percentage&of&apoptotic& and& active& caspaseQ3& positive& cells& was& determined& by& flow& cytometry& after&staining&with& AnnexinQV/7AAD& and& antiQcaspaseQ3QFITC& antibodies,& respectively& (Fig.& 7A&and& B).& & All& nested& deletion& clones& except& for& Hsp27& Δ104Q205& were& able& to& reduce&apoptotic& cells& and& active& caspaseQ3+& cells& by& about& 75%& (Fig.& 7A& and& B,& bars& AQE).&&Overexpression&of&Hsp27&Δ104Q205&resulted&in&apoptotic&and&active&caspaseQ3+&cell& levels&similar&to&the&empty&mycQvector&control&(Fig.&7A&and&B,&bar&F).&&&In&addition,&the&enzymatic&activity&of&caspaseQ3&and&Q9&was&determined&in&the&same&samples&using&the&DEVDQAFC&and&LEHDQAFC&assays,&respectively&(Fig.&7C&and&D).&&CaspaseQ3&activity&was&significantly&inhibited&by&about&50%&by&all&deletions&except&for&Hsp27&Δ104Q205&(clone&F)&(Fig.&7C,&bars&AQE).& &However,&although&caspaseQ9&activity&was&still&inhibited&by&about&40%&through&deletions&of&Hsp27&aa&154Q205&(Fig.&7D,&bars&AQC),&beginning&with&Hsp27& Δ137Q205,& caspaseQ9& inhibition& lost& statistical& significance& and& was& gradually&restored&with&each&successive&deletion&(Fig.&7D,&bars&DQF).&Altogether,& these& results& show& that& Hsp27& Δ154Q205& has& decreased& binding& to&caspaseQ3&but&is&still&able&to&inhibit&apoptosis.& &In&addition,&Hsp27&Δ104Q205&is&not&able&to&bind&to&caspaseQ3&and&does&not&inhibit&caspaseQ3&activity&or&apoptosis,&suggesting&that&the&loss& in&binding&of&Hsp27&Δ154Q205& to& caspaseQ3& is&not& essential& for& its& ability& to&prevent&caspaseQ3&activity.& &This&could&occur& if& the&reduced&binding&was&still& sufficient& to&prevent&caspaseQ3& activation& or& if& Hsp27& Δ154Q205& is& still& able& to& inhibit& the& apoptotic& signaling&cascade&upstream&of&caspaseQ3.&&&
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3.4!Structural!Prediction!of!Hsp27ECaspaseE3!Interaction!& The&regions&of&Hsp27&between&aa&104Q119&and&aa&154Q186&were&both& found&to&be&potential& binding& domains& for& the& inhibition& of& caspaseQ3& activity.& & To& better& understand&this&mechanism,& structural& features&within&each&domain& that&could&contribute& to&proteinQprotein&interactions&were&studied&based&on&protein&crystal&structures.& &A&limitation&of&this&approach&however&is&that&human&Hsp27&has&not&yet&been&successfully&crystallized.&&So&far,&only& four& complete& evolutionarily& related& sHsp& structures& have& been& resolved& by& xQray&crystallography& (91Q94).& & Hsp16.5& is& an& archaean& protein& purified& from&Methanococcus%
janaschii,&which&was& the& first& crystallized&sHsp&and&shares&15%&sequence&homology&with&Hsp27&(91).& &The&protein&consists&of&24&monomers&arranged&in&a&roughly&spherical&shape&(Fig.&8A).&&The&wheat&(Triticum%aestivum)&Hsp16.9&is&made&of&12&monomers&that&form&two&backQtoQback&hexameric&rings&and&is&17%&similar&to&Hsp27&(Fig.&8B),&while&the&Tsp36&is&a&flatworm&(Taenia%saginata)&sHsp&that&forms&a&functional&dimer&and&is&25%&homologous&to&Hsp27& (Fig.& 8C)& (92,94).& & The& most& recent& sHsp& to& be& crystallized& is& the& bacterial&(Xanthomonas%axonopodis)& sHspA,&which&shares&17%&sequence& identity&with&Hsp27&(93).&&Although& the& protein& forms& a& functional& 36Qmer,& only& the& dimer& structure& is& currently&available&through&the&Protein&Data&Bank&for&analysis&(Fig.&8D).&& Each& of& the& crystallized& sHsps&was& assessed& for& its& ability& to& serve& as& a&model& for&Hsp27& quaternary& structure& by& comparing& sequence& and& secondary& structure& homology&information&available&in&the&literature.&&The&bacteria&sHspA&was&not&included&in&the&analysis&as& its& full& structure& is&not&yet&available.& & Several&key& features&define&a& sHsp& including& the&presence& of& a& αQcrystallin& domain,& the& formation& of& a& homodimer& in& an& antiQparallel&orientation,& and& the& formation& of& large& oligomeric& structures& using& the& homodimers& as&
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building& blocks& (40).& & The& monomers& of& Tsp36& only& form& dimers& in& a& perpendicular&orientation,&and&each&monomer&contains&two&αQcrystallin&domains&(94).& &However,&Hsp27&has&been&shown&to&form&antiQparallel&dimers&and&oligomeric&structures&as&large&as&400&kDa,&and& it&contains&only&one&αQcrystallin&domain&(95,96).& &Due&to&the&structural&discrepancies&between& Hsp27& and& Tsp36,& the& flatworm& protein& would& not& serve& as& a& good& model& for&Hsp27& structure& and&was& therefore& excluded& from& further& analysis.& & The& remaining& two&structures,&Hsp16.5&and&Hsp16.9,&posess&the&typical&features&of&a&sHsp&described&above&and&are& very& structurally& similar.& & The& two& proteins& do& however& differ& on& the& number& of&residues&between&their&ninth&and&tenth&βQstrands,&which&is&believed&to&be&important&in&the&determination&of&quaternary&structure&(41).& &Hsp16.9&has&more&residues&between&β9&and&β10,&which& leads& to& the& formation&of& a& “hinge”& that& is& crucial& for& its& oligomeric& structure&(92).&&Hsp16.5&has&fewer&aa&between&the&same&two&strands&and&is&therefore&unable&to&form&a& similar& “hinge,”& resulting& in&a&very&different&quaternary& structure& (91).& &Hsp27&has& few&residues& between& β9& and& β10,& suggesting& that& it& may& develop& an& oligomeric& structure&similar& to& that& of& Hsp16.5.& & Therefore,&we& chose& to& utilize&Hsp16.5& as& a&model& of& Hsp27&structure.&& In&order&to&examine&the&structural&features&of&Hsp27,&the&Swiss&Model&program&was&used&to&generate&an&Hsp27&model&based&on&the&model&of&Hsp16.5&(Fig.&9A).&&In&addition,&the&Deep& View& program& was& utilized& to& calculate& the& accessibility& of& the& aa& within& the& αQcrystallin&domain&(Fig.&9B).& &Analyzing&known&binding&domains&of&other&proteins&revealed&that&aa&require&at&least&25%&accessibility&for&proteinQprotein&interactions,&as&calculated&by&Deep&View.& &Within& the& first&potential& caspaseQ3&binding&region& that& contains&aa&104Q119&(Fig.&9,&yellow)&most&of&the&residues&are&buried,&though&aa&104Q106&are&accessible&enough&
& 34&
for& proteinQprotein& interactions& (Fig.& 9,& purple).& & Interestingly,& within& the& structure& this&corresponds& to& a& small& loop& that& rises& away& from& the& surface& of& the& protein& (Fig.& 9A,&purple).& & The& second&potential& caspaseQ3&binding& region,& aa&154Q186,& contains&numerous&regions& of& accessibility,& though& it& lacks& a& loop,& groove,& or& other& obvious& structures& for&proteinQprotein&interactions&(Fig.&9A,&white).& &Due&to&the&limitations&of&using&the&structure&of&Hsp16.5&as&a&model,&Hsp27&aa&187Q205&are&unaccounted&for&since&Hsp16.5&is&comprised&of&just&147&aa,&and&their&presence&could&lower&the&accessibility&of&the&aa&within&the&second&potential& caspseQ3& binding& region.& & Altogether,& these& results& support& the& hypothesis& that&Hsp27&aa&104Q119&and&aa&154Q186&are&important&for&the&association&with&caspaseQ3.&
!
3.5!Conclusion!& This&study&investigated&the&interaction&between&Hsp27&and&caspaseQ3&to&define&the&Hsp27&peptide&region&essential&for&the&inhibition&of&caspaseQ3&activation&during&apoptosis.&&Using&Hsp27&deletion&clones,&we&were&able&to&define&that&the&binding&region&is&possibly&aa&104Q119,&aa&154Q186,&or&contributed&to&by&both&aa&regions.&&We&discovered&that&while&loss&of&aa&154Q186&causes&a&reduction&in&Hsp27&association&to&caspaseQ3,&Hsp27&is&still&able&to&inhibit&caspaseQ3&activity&and&apoptosis&in&cardiomyocytes.&&This&may&indicate&that&aa&154Q186& is& a& nonQessential& binding& region& or& that& Hsp27& Δ154Q205& is& still& able& to& inhibit&apoptosis& upstream& of& caspaseQ3& activation.& & Furthermore,& Hsp27& protection& of&cardiomyocytes& from& doxQinduced& apoptosis& and& caspaseQ3& activity& is& not& lost& until& the&deletion& of& aa& 104Q119,& suggesting& this& region& is& vitally& important& to& the& execution& of&apoptosis&mediated& by& caspaseQ3.& & To& further& investigate& Hsp27& structural& features& that&could& contribute& to& proteinQprotein& interactions,& we& utilized& Hsp16.5& as& a& model& for&
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quaternary& structure.& &We& analyzed& the& accessibility& of&Hsp27& aa&modeled& after&Hsp16.5&and&found&that&aa&regions&104Q119&and&154Q186&both&contain&residues&accessible&enough&for& proteinQprotein& interactions.& & These& results& suggest& that& Hsp27& regulates& caspaseQ3&activation& through& an& interaction& between& Hsp27& aa& 104Q119& and& 154Q186& and& the&prodomain&of&caspaseQ3.&&This&study&contributes&to&the&understanding&of&the&mechanism&by&which& Hsp27& inhibits& caspaseQ3& activity& and& will& lead& to& the& development& of& a& peptide&therapy&to&prevent&cardiomyocyte&apoptosis&during&dox&treatment.&
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Figure 2. Structures of some common anthracyclines.  A: Doxorubicin (dox), one of the first 
isolated anthracyclines and the most commonly used for the treatment of many cancers.  B: 
Danorubicin (dan), one of the first isolated anthracyclines.  C: Epicubicin, an analog of dox.  D: 
























Lane 1 2 3 4 5 6 7
Figure 3. Hsp27 C-terminal associates with caspase-3 to inhibit its activity.  A: Schematic 
representation of human Hsp27.  B: Extracts from HeLa cells transiently transfected with myc-tagged 
Hsp27 FL, N-term, or C-term were immunoprecipitated (IP) with anti-caspase-3 antibodies or an 
isotype control (lane 1).  IPs were analyzed by immunoblotting with anti-myc and anti-caspase-3.  
C-D: Purified human recombinant 6 x His-tagged caspase-3 and 6 x His-tagged Hsp27 were 
incubated for 30 min at 4°C.  Following the caspase-3:Hsp27 complex formation,  recombinant 
active-caspase-9 was added to induce the first cleavage of caspase-3.  Caspase-3 activity was 
determined by the DEVD-AFC activity assay, while the processing of caspase-3 was followed by 
western blot analysis using anti-caspase-3 antibodies.  Results were obtained from three independent 
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HSPB1 human           80  QLSSGVSEI---RHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGY---ISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLAT--QSNEITIPVTFE 186
HSPB1 chimpanzee      80  QLSSGVSEI---RHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGY---ISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLAT--QSNEITIPVTFE 170
HSPB1 mouse           84  QLSSGVSEI---RQTADRWRVSLDVNHFAPEELTVKTKEGVVEITGKHEERQDEHGY---ISRCFTRKYTLPPGVDPTLVSSSLSPEGTLTVEAPLPKAVT--QSAEITIPVTFE 190
HSPB1 rat             84  QLSSGVSEI---RQTADRWRVSLDVNHFAPEELTVKTKEGVVEITGKHEERQDEHGY---ISRCFTRKYTLPPGVDPTLVSSSLSPEGTLTVEAPLPKAVT--QSAEITIPVTFE 190
HSPB1 cow             76  QLSSGVSEI---QQTADRWRVSLDVNHFAPEELTVKTKDGVVEITGKHEERQDEHGY---ISRCFTRKYTLPPGVDPTLVSSSLSPEGTLTVEAPLPKSAT--QSAEITIPVTFQ 182
HSPB1 xenopus         88  QLSSGISEI---RQTSDQWKISLDVNHFAPEELVVKTKDGIVEITGKHEEKQDEHGF---ISRCFTRKYTLPPGVAINAVASSLSPDGILTVEAPLPKPAI--QSAEISIPITFQ 194
HSPB1 zebrafish       87  QLSSGMSEV---KQTGDSWKISLDVNHFSPEELNVKTKDGVLEITGKHEERKDEHGF---ISRCFTRKYTLPPGVDSEKISSCLSPEGVLTVEAPLPKPAI--QAPEVNIPVNKT 193 
HSPB1 chicken         78  QLSSGISEI---RQSADSWKVTLDVNHFAPEELVVKGKERIGRTKSKHEEKQDEHGF---ISRCFTRKYTLPPGVEATAVRSSLSPDGMLTVEAPLPKPAI--QSSEITIPVTVE 184
HSPB1 Drosophila      73  RASGGPNAL-LPAVGKDGFQVCMDVSQFKPNELTVKVVDNTVVVEGKHEEREDGHGM---IQRHFVRKYTLPKGFDPNEVVSTVSSDGVLTLKAPPPPSKE--QAKSERIVQIQQ 178
HSPB1 C. elegans      125 NLKSPL--I-KDESDGKTLRLRFDVANYKPEEVTVKTIDNRLLVHAKHEEKTPQR-T---VFREYNQEFLLPRGTNPEQISSTLSTDGVLTVEAPLPQLAI--QQ---------- 219
CRYAA human           56  VLDSGISEV---RSDRDKFVIFLDVKHFSPEDLTVKVQDDFVEIHGKHNERQDDHGY---ISREFHRRYRLPSNVDQSALSCSLSADGMLTFCGPKIQTGLDATHAERAIPVSRE 165
CRYAB human           59  WFDTGLSEM---RLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGF---ISREFHRKYRIPADVDPLTITSSLSSDGVLTVNGPRKQV----SGPERTIPITRE 164
HSPB6 human           61  --ALPVAQV---PTDPGHFSVLLDVKHFSPEEIAVKVVGEHVEVHARHEERPDEHGF---VAREFHRRYRLPPGVDPAAVTSALSPEGVLSIQAAPASAQAPPPAAAK------- 160
HSPB7 human           66  ARPGGAGNI---KTLGDAYEFAVDVRDFSPEDIIVTTSNNHIEVRA---EKLAADGT---VMNTFAHKCQLPEDVDPTSVTSALREDGSLTIRARRHPHTEHVQQTFRTEIKI-- 170
HSPB8 human           82  ----AEGRT-PPPFPGEPWKVCVNVHSFKPEELMVKTKDGYVEVSGKHEEKQQEGGI---VSKNFTKKIQLPAEVDPVTVFASLSPEGLLIIEAPQVPPYS--TFGESSFNNELP 191
HSPB9 human           36  LLRDSPAAQEDNDHARDGFQMKLDAHGFAPEELVVQVDGQWLMVTGQQQLDVRDPERVSYRMSQKVHRKMLPSNLSPTAMTCCLTPSGQLWVRGQCVALALPEAQTGPSPRLGSL 150
HSPB10 human          107 KLRRTTNRILASSCCSSNILGSVNVCGFEPDQVKVRVKDGKVCVSAERENRYDCLGSKKYSYMNICKEFSLPPCVDEKDVTYSYGLGSCVKIESPCYPCTSPCSPCSPCSPCN-- 227
88 104 120 137 154
IRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFE
ȕ ȕ ȕ ȕ ȕ ȕĮĮ
104 120 137 154





































































Figure 5. Generation of Hsp27 deletion mutants in mammalian expression vectors. 
A: Hsp27 clones were amplified by PCR with forward (FP) and reverse (RP) primers 
(Table 2) flanking the regions of interest.  Hsp27 DNA inserts (a-e) were ligated into the 
mammalian expression vector pCDNA3-5 x myc.  B: Hsp27 deletion PCR products were 
run on a 1% agarose gel.  C: Agarose gel restriction enzyme analysis  using BamHI and 
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Figure 6. Effect of myc-tagged Hsp27 deletion mutants on the association with 
caspase-3.  Lysates from HeLa cells transiently transfected with Hsp27 clones were 
immunoprecipitated (IP) using anti-caspase-3 or IgG control antibodies (lane 1).  IP 
and Input were analyzed by immunoblotting with anti-myc  and anti-caspase-3 






























































Figure 7. Hsp27 C-terminal deletion clones inhibit caspase activity.  +FUDWFDUGLRP\RF\WHFHOOV
ZHUH WUDQVLHQWO\ WUDQVIHFWHG ZLWK P\FWDJJHG +VS GHOHWLRQ PXWDQWV DQG WUHDWHG ZLWK  0
GR[RUXELFLQGR[RU'062GLOXHQWFRQWUROIRUKA-B: 3HUFHQWDJHRIDSRSWRWLFFHOOVDQGDFWLYH
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Figure 8. Comparison of completely resolved sHsp crystal structures.  The sHsps 
with completely crystallized oligomeric structures were examined for their ability to serve 
as a model for the yet unresolved Hsp27 structure.  A: Structure of Methanococcus 
janaschii (archaean) Hsp16.5, a spherical oligomer made of 24 monomer subunits (91).  
Hsp16.5 was determined to be the most suitable structural model for Hsp27 based on 
sequence homology and secondary structure similarity.  B: Structure of Triticum aestivum 
(wheat) Hsp16.9, composed of two hexameric rings (92).  C: Structure of Taenia saginata 
IODWZRUP 7VS D GLPHU ZLWK WZR ĮFU\VWDOOLQ GRPDLQV SHU VXEXQLW  D: Partial 
structure of Xanthomonas axonopodis (bacteria) sHspA which forms a functional 
GRGHFDPHUEOXH 1WHUPLQDOEODFN &WHUPLQDO\HOORZ UHJLRQFRUUHVSRQGLQJWR
+VSDDZKLWH UHJLRQFRUUHVSRQGLQJWR+VSDD
42
Figure 9. Hsp16.5 can serve as a structural model for Hsp27.  A: Human Hsp27 
modeled after archaean Hsp16.5 crystal structure with zoomed view and potential 
interaction loops (aa 104-106) highlighted in purple.  B: Accessibility of Hsp27 model aa 
calculated by Deep View program to determine regions available for protein-protein 
interactions.  (blue = N-terminal; black = C-terminal; yellow = first potential caspase-3 
binding domain (aa 104-120); purple = most accessible aa within binding domain, aa 








4.1!Introduction!& NonQsmall& cell& lung& carcinomas& (NSCLC)& are& some& of& the& most& common& and&deadliest& types& of& cancers& in& the& United& States.& & The& three& NSCLC& subtypes,&adenocarcinomas&(ACC),&squamous&cell&carcinomas&(SCC),&and&large&cell&carcinomas&(LCC),&are&often& found&at& the&advanced&stage&when& the&cancer&has&metastasized& to&other&organs&and& treatment& options& are& limited& and& ineffective.& & The& tumor& necrosis& factorQrelated&apoptosisQinducing&ligand&(TRAIL)&has&emerged&as&a&promising&antiQcancer&drug&due&to&its&ability& to& selectively& induce& apoptosis& via& the& death& receptors& (DR)& 4& and& 5& in& various&malignancies,&including&cervical&and&lung&cancers&and&leukemia,&while&leaving&normal&cells&unaffected&(97Q99).&&TRAIL&induces&cell&death&via&the&extrinsic&pathway&by&binding&to&DR4&or&DR5&resulting&in&the&formation&of&the&DISC&complex&and&subsequent&caspaseQ8&activation&(19).&&Normal&cells&express&low&levels&of&DR4&and&DR5,&but&high&levels&of&decoy&receptor&1&and& 2& (DcR1& and& DcR2),& which& are& structurally& similar& to& DR4& and& DR5,& but& lack& an&intracellular&death&domain&to& transmit& the&apoptotic&signal&(100).& &Through&a&mechanism&that& is&not&well&understood,& transformed&cells&express&more&DR4&and&DR5&and& less&DcR1&and&DcR2,& thus& accounting& for& the& TRAIL& sensitivity& of&many& colon,& breast,& kidney,& skin,&prostate,& and& ovarian& cancers& (98Q100).& & However,& not& all& transformed& cells& switch& from&decoy&receptor&to&death&receptor&expression,&and&as&a&result,&some&cancers&have&been&found&to& be& resistant& to& TRAIL& (100).& & In& addition,& Hsp70& has& been& shown& to& bind& to& the&intracellular& domain& of& DR5& thereby& preventing& the& formation& of& the& DISC& complex& and&
& 45&
activation&of&caspaseQ8,&providing&an&additional&mechanism&that&mediates&TRAIL&resistance&(101).& & Although& TRAIL& is& not& yet& FDAQapproved,& its& clinical& relevance& was& recently&assessed& in& a& Phase& II& clinical& trial& (data& not& yet& published;&http://clinicaltrials.gov/ct2/show/record/NCT00508625).&&Some&adverse&side&effects&have&been&observed& in&TRAILQresistant& cells& including& the&promotion&of& tumor&cell& invasion& in&pancreatic&ductal&adenocarcinoma&and&colorectal&cancer&models,&suggesting&that&TRAIL&has&a&proQtumorigenic&role& in&resistant&cancer&cells& (102,103).& &Approximately&50%&of&NSCLC&are& resistant& to& TRAIL& unless& given& in& combination& with& various& other& agents& that& can&sensitize&the&cells&to&TRAIL&treatment,&with&no&particular&bias&for&one&NSCLC&subtype&(104).&&Therefore,&recent&interest&has&been&focused&on&identifying&novel&therapeutics&that&can&aid&in& the& sensitization& of& NSCLC& to& TRAIL& treatment& by& decreasing& or& inactivating& antiQapoptotic& proteins& while& simultaneously& upQregulating& or& activating& proQapoptotic&molecules.&& Flavonoids&induce&changes&in&signal&transduction&pathways&related&to&apoptosis&by&promoting& the& inactivation& of& the& survival& kinase,& Akt& (also& known& as& Protein& kinase& B),&activation&of& caspaseQ3,&upQregulation&of&DRs,& and&decreased&expression&of& antiQapoptotic&proteins&including&XIAP&and&sHsps&such&as&Hsp27&(48,61,105Q107).&&Some&flavonoids&have&been& shown& to& induce& apoptosis& in& the& absence& of& a& chemotherapeutic& drug,& like& the&flavones& luteolin& (Fig.& 1C)& in&NSCLC& and& apigenin& (Fig.& 1B)& in& leukemia& (61,108).& & Other&studies&have&shown&that&luteolin&and&the&flavonols&quercetin&(Fig.&1D)&and&kaempferol&(Fig.&1E)&improve&the&effectiveness&of&chemotherapy&drugs&like&doxorubicin&(dox)&or&cisplatin&to&induce& apoptosis& in& resistant& pancreatic,& prostate,& and& breast& cancers& as& well& as& NSCLC&(105Q107).&&In&addition,&cervical&cancer&cells&are&sensitized&to&TRAIL&treatment&by&flavone,&
& 46&
apigenin,& and& the& isoflavone& genistein& (Fig.& 1F)& through& an& undetermined& mechanism&(109).&& In& some& cases,& flavonoidQinduced& sensitization& to& chemotherapy& drugs& has& been&shown&to&be&caused&by& their&effects&on&proteins& involved& in&apoptosis& (53,59,60).& &Hsp27&expression& was& found& to& be& upregulated& in& numerous& cancers,& including& breast,&endometrial,& lung,&and&prostate&cancers,&and& it& is&commonly&used&as&a&prognostic&marker&(110).& & Importantly,& the& downQregulation& of& Hsp27& expression& by& siRNA& sensitized& the&NSCLC& cell& line& A549& to& TRAILQinduced& apoptosis& (83).& & The& flavonoids& quercetin,&kaempferol,& and& luteolin& are& all& able& to& reduce& Hsp27& expression& via& an& undetermined&mechanism& that& involves& the& downregulation& of& Hsp27& mRNA& (111Q113).& & Quercetin,&genistein,& and&kaempferol& further& increase& the& level&of& apoptosis&via& the&upQregulation&of&Bax,&the&downQregulation&of&BclQXL,&BclQ2,&and&XIAP,&and&increased&cytosolic&cytochrome&C&in& leukemia& and& lung,& prostate,& pancreatic,& and& breast& cancers& (105,106,114).& & Another&important&molecule& regulated& by& flavonoids& is& the& TRAIL& receptor& DR5,&which& has& been&shown& to& contribute& more& to& apoptotic& signaling& than& DR4& (115).& & DR5& expression&increases&with& quercetin& or& naringenin& (Fig.& 1G)& treatment& in& lung& cancers& and& apigenin&treatment& in& leukemia,& prostate& cancer,& and& colon& cancer,& thereby& conferring& greater&sensitivity& to& TRAIL& treatment& (116Q118).& & However,& the& ability& of& apigenin& to& sensitize&NSCLC& to&TRAILQinduced&apoptosis& and& the&mechanism&by&which& this&may&occur&has&not&been&studied.&& In& this& study,& the& efficacy& of& the& flavone& apigenin& to& sensitize& NSCLC& cell& lines& to&TRAILQinduced& apoptosis& was& assessed& and& the& mechanism& by& which& the& sensitization&occurs& was& identified.& & For& this& purpose,& four& cell& lines& were& utilized& that& were&
& 47&
representative& of& the& types& and& stages& of& NSCLC,& which& included& A549& (ACC,& Stage& I),&H2009&(ACC,&Stage&IV),&CaluQ1&(SCC),&and&H1299&(LCC).&&Our&findings&showed&that&apigenin&and&TRAIL&function&in&a&synergistic&manner&to&promote&caspaseQ3&dependent&apoptosis&in&all&four&NSCLC&cell&lines.&&We&further&identified&novel&aspects&in&the&mechanism&responsible&for& apigenin& sensitization,& which& involved& the& downQregulation& of& the& antiQapoptotic&proteins&XIAP&and&Hsp27,&upQregulation&of&DR5,&and&disruption&of&the&interaction&between&Hsp70&and&DR5.&&Collectively,&these&findings&support&a&model&in&which&apigenin&modulates&the& function& of& proQ& and& antiQapoptotic& molecules& at& multiple& cellular& checkpoints& to&promote&TRAILQinduced&apoptosis&in&NSCLCs.&&
4.2!Apigenin!and!TRAIL!Act!Synergistically!to!Induce!Apoptosis!in!NSCLC!& In&order&to&determine&the&effect&of&apigenin&and&TRAIL&combination&treatments&on&NSCLC& cells,& four& cell& lines& were& utilized& that& represent& the& three& subtypes& of& NSCLC& at&various& stages,&which& included&A549& (ACC,&Stage& I),&H2009& (ACC,&Stage& IV),&CaluQ1& (SCC),&and&H1299& (LCC).& &The&effect&of& combination& treatments&was&assessed&by&measuring& cell&viability& using& the&MTT& assay.& Cells&were& treated&with& 1,& 10,& 25,& and& 50& µM& apigenin& or&DMSOQdiluent& control& for& 24& h& prior& to& the& addition& of& 25,& 50,& and& 100& ng/ml& TRAIL& or&TRAILQbuffer& control& for& an& additional& 24& h.& & In& A549& cells,& treatments& with& the& DMSOQdiluent&control,&1,&or&10&µM&apigenin&had&no&effect&on&cell&viability&at&any&concentration&of&TRAIL&tested&(Fig.&10A,&diamonds,&squares,&and&triangles).&&However,&in&the&presence&of&25&µM&apigenin,&50%&of&cells& lost&viability&when& in&combination&with&100&ng/ml&TRAIL&(Fig.&10A,& circles).& & In& the& presence& of& 50& µM& apigenin,& only& 40%& of& cells& were& viable& at& all&concentrations&of&TRAIL&tested&(Fig.&10A,&inverted&triangles).&&Similar&to&A549&cells,&H2009&
& 48&
cells&were&unaffected&by&1&and&10&µM&apigenin&treatments&(Fig.&10A,&squares&and&triangles).&&The&addition&of&either&25&or&50&µM&apigenin&alone&resulted&in&a&40%&loss& in&cell&viability,&while&the&combination&treatments&of&25&or&50&µM&apigenin&with&100&ng/ml&TRAIL&caused&a&further& loss&of&80%& in& cell& viability& (Fig.&10A,& circles& and& inverted& triangles).& & CaluQ1&and&H1299&cells&responded&to&combination&treatments&similarly,&with&less&than&10%&loss&in&cell&viability&observed&for&1&µM&apigenin&treatments&at&all&concentrations&of&TRAIL&tested&(Fig.&10A,& squares).& & CaluQ1& cells& showed& 60%& cell& viability& with& 10& and& 25& µM& apigenin&treatment&when&combined&with&100&ng/ml&TRAIL& (Fig.&10A,& triangles&and&circles),&which&decreased& to& 25%& cell& viability& with& 50& µM& apigenin& treatment& at& all& concentrations& of&TRAIL&tested&(Fig.&10A,& inverted&triangles).& &Similar&to&H2009&cells,&H1299&cells&showed&a&sensitivity& to&10,&25,&and&50&µM&apigenin&treatment&that&when&combined&with&100&ng/ml&TRAIL& resulted& in& 50%,& 40%,& and& 20%& cell& viability,& respectively& (Fig.& 10A,& triangles,&circles,& and& inverted& triangles).& & Our& data& showed& that& 25& and& 50& µM& apigenin& cause& a&significant& (p<0.0001)& loss& in& cell& viability& in& all& cell& lines& as& compared& to& no& apigenin&treatment& (Fig.& 10A,& circles& and& inverted& triangles).& & In& addition,& the& 10& µM& apigenin&treatment& induced& significantly& lower& cell& viability& in& CaluQ1& (p<0.0001)& and& H1299&(p<0.01)& cells& (Fig.& 10A,& triangles).& & These& results& suggest& that& apigenin& and& TRAIL&combination& treatments& are& able& to& reduce& cell& viability& significantly& more& than& either&treatment&alone.&& To&determine&whether&the&observed&effect&of&combination&treatment&on&cell&viability&is& the& result& of& an& additive,& synergistic,& or& antagonistic& drug& effect,& isobolograms& were&generated&(Fig.&10B).&&The&IC50&of&apigenin&treatment&alone&and&TRAIL&treatment&alone&was&used& to& construct& the& line& of& additivity& for& the& isobologram& of& each& cell& line,& and& the&
& 49&
combination&index&(CI)&was&calculated&using&the&formula&described&in&section&2.12&(Table&4).&&The&combination&treatment&for&all&cell&lines&was&found&to&have&a&CI&<&1,&suggesting&that&apigenin&and&TRAIL&function&synergistically,&meaning&the&effects&of&TRAIL&are&enhanced&by&apigenin& treatment.& & A& lower& CI,& such& as& 0.173& calculated& for&H2009,&may& indicate&more&synergism& than& the& A549& CI& of& 0.557,& but& given& that& the& calculated& CI& is& based& on&estimations&(IC50),&the&error&and&significance&of&each&CI&cannot&be&determined.&& &&&&&&&Table!4.!Calculated!IC50!and!Combination!Index!
!A50&=& IC50&of&apigenin&alone,&T50&=& IC50&of&TRAIL&alone,&C50&=& IC50&of&apigenin&when&combined&with&100&ng/ml&TRAIL,&CI&=&combination&index&&& Further&characterization&of&the&apigenin&and&TRAIL&combination&treated&NSCLC&cells&was& done& by& analyzing& the& contribution& of& apoptosis& to& the& observed& decreased& cell&viability.& &For&this&purpose,&cells&were&treated&with&two&concentrations&of&apigenin.& &A549&and&CaluQ1&cells&were&treated&with&25&and&50&µM&apigenin,&while&H2009&and&H1299&cells&were&treated&with&10&and&25&µM&apigenin&for&18&h&followed&by&an&additional&6&h&with&25,&50,&or&100&ng/ml&TRAIL.&&Apoptosis&was&evaluated&by&staining&with&Annexin&VQAPC/7QAAD&and& antiQactive& caspaseQ3QFITC.& & In& all& cell& lines,& DMSOQdiluent& controlQtreated& cells&exhibited&apoptosis&and&active&caspaseQ3&in&less&than&8%&of&cells&[Fig.&11A&and&B,&TRAIL&(Q)/Apigenin&(Q)].&&Apigenin&and&TRAIL&treatment&alone&showed&7Q12%&apoptotic&and&active&caspaseQ3&cells,&which&was&not& found& to&be&statistically&significant&when&compared& to& the&DMSOQcontrol&[Fig.&11A&and&B,&TRAIL&(Q)/Apigenin&(25&or&50)&and&TRAIL&(100)/Apigenin&(Q
Cell Line A50 (µM) T50 (ng/ml) C50 (µM) CI
A549 60.55 1.87 x 1014 33.74 0.557
H2009 129.52 1631.00 14.47 0.173
Calu-1 172.88 8856.00 22.72 0.131
H1299 169.82 1.95 x 1011 10.00 0.059
& 50&
)].& & Combination& treatments& increased& apoptosis& and& active& caspaseQ3& ranging& from&15%&for&the&lowest&concentrations&of&apigenin&and&TRAIL&to&37%&for&the&highest&concentrations&(Fig.&11A&and&B).& & In&A549&cells,&combination&treatments&with&25&µM&apigenin&resulted& in&apoptosis& in& about& 20%& of& cells,& while& 50& µM& apigenin& induced& 30%& apoptosis& in& all&concentrations&of&TRAIL&used&(Fig.&11A).& &H1299&cells&showed&a&response&similar&to&A549&cells&with&combination&treatments&(Fig.&11A).&&In&H2009&and&CaluQ1&cells,&the&percentage&of&apoptotic&cells&gradually&increased&with&increasing&TRAIL&concentration&for&each&apigenin&concentration& (Fig.& 11A).& & However,& in& all& cell& lines,& samples& treated& with& the& same&concentration& of& apigenin& were& not& found& to& have& a& statistically& significant& increase& in&apoptotic& cells&when& treated&with& different& concentrations& of& TRAIL.& & Staining& for& active&caspaseQ3&in&A549&cells&after&25&µM&apigenin&and&25&ng/ml&TRAIL&treatment&showed&10%&positive& cells,&which& increased& to& about& 20%&with& 50& ng/ml& TRAIL& or& 100& ng/ml& TRAIL&treatment&(Fig.&11B).&&Increasing&TRAIL&concentration&in&combination&with&50&µM&apigenin&gradually& increased& the& percentage& of& active& caspaseQ3+& cells& from& 29%& to& 34%& in& A549&cells& (Fig.& 11B).& & CaluQ1& cells& also& showed& a& gradual& increase& in& active& caspaseQ3& with&increasing& TRAIL& and& apigenin& concentration& (Fig.& 11B).& & Both& H2009& and& H1299& cells&showed&15Q20%&active&caspaseQ3+&cells&when&treated&with&10&µM&apigenin&and&about&30%&active&caspaseQ3+&cells&with&25&µM&apigenin&(Fig.&11B).& &However,&in&all&cell& lines,&samples&treated& with& the& same& concentration& of& apigenin& were& not& found& to& have& a& statistically&significant&increase&in&active&caspaseQ3+&cells&when&treated&with&different&concentrations&of&TRAIL.& & The& two& concentrations& of& apigenin& used& in& each& cell& line& showed& a& significant&difference& in& the& percentage& of& apoptotic& and& active& caspaseQ3+& cells& & (Fig.& 11,& bracketed&
& 51&
groups,& ****& p<0.0001,& ***& p<0.001).& & These& results& show& that& apigenin& and& TRAIL&combination&treatments&induce&caspaseQ3Qdependent&apoptosis&in&NSCLC.&& The&specific&apoptotic&pathway&(intrinsic&or&extrinsic)&involved&in&the&promotion&of&apoptosis& by& apigenin& and&TRAIL& treatments&was&determined&by& caspase& activity& assays.&&NSCLC&cells&were&treated&with&apigenin&for&18&h&(25&and&50&µM&for&A549&and&CaluQ1,&10&and&25&µM&for&H2009&and&H1299)&prior&to&the&addition&of&25,&50,&or&100&ng/ml&TRAIL&for&6&h.&&The&activity&of&caspaseQ3&and&Q8&was&determined&using&the&DEVDQAFC&and&IETDQAFC&assays,&respectively& (Fig.& 12).& & In& A549& cells,& control,& apigenin& alone,& or& TRAIL& alone& all& showed&very& little& caspaseQ3& activity,& and& individual& treatments&were& not& statistically& significant,&which& was& also& shown& in& H2009& and& CaluQ1& cells& (Fig.& 12A).& & Treatment& with& 25& µM&apigenin&increased&caspaseQ3&activity&when&combined&with&TRAIL,&with&50&and&100&ng/ml&TRAIL&showing&a&similar&activity&level&at&50&nM&AFC/min/mg&protein&compared&to&30&nM&AFC/min/mg&protein&with&25&ng/ml&TRAIL&(Fig.&12A).& &CaspaseQ3&activity& increased&with&50&µM&apigenin&to&60&nM&AFC/min/mg&protein&when&combined&with&25&ng/ml&TRAIL&and&75& nM& AFC/min/mg& protein& with& 50& and& 100& ng/ml& TRAIL& (Fig.& 12A).& & H1299& cells&followed& a& similar& profile& of& increasing& caspaseQ3& activity& with& increasing& apigenin& and&TRAIL& concentration,& with& the& exception& that& treatment& with& TRAIL& alone& induced&significantly& higher& caspaseQ3& activity& (p<0.0001)& compared& to& the& control& sample& (Fig.&12A).& & H2009& cells& showed& low& levels& of& caspaseQ3& activity& when& treated& with& 10& µM&apigenin& combined& with& 25& or& 50& ng/ml& TRAIL& (10& nM& AFC/min/mg& protein)& that& was&dramatically& increased&with&100&ng/ml&TRAIL&(80&nM&AFC/min/mg&protein),& though&still&not&calculated&to&be&statistically&significant&(Fig.&12A).&&Furthermore,&H2009&treated&with&25&µM& apigenin& in& combination& with& 25& or& 50& ng/ml& TRAIL& also& showed& lower& caspaseQ3&
& 52&
activity& (75& nM& AFC/min/mg& protein)& as& compared& to& combination& treatment& with& 100&ng/ml& TRAIL& (160& nM& AFC/min/mg& protein)& (Fig.& 12A).& & CaluQ1& cells& showed& caspaseQ3&activity&of&about&170&nM&AFC/min/mg&protein&for&all&combination&treatments&of&apigenin&and&TRAIL&tested&(Fig.&12A).& &With&the&exception&of&CaluQ1&cells,&all&cell& lines&showed&that&increasing&apigenin&treatment&resulted&in&significantly&higher&caspaseQ3&activity&across&the&range&of&TRAIL& concentrations& tested& (Fig.& 12A,&bracketed&groups,& *&p<0.05,& ***&p<0.001,&****&p<0.0001).&&However,&in&all&cell&lines,&samples&treated&with&the&same&concentration&of&apigenin& were& not& found& to& have& a& statistically& significant& increase& in& caspaseQ3& activity&when&treated&with&different&concentrations&of&TRAIL.&&In&parallel,&the&activity&of&caspaseQ8&was&assessed& in&H1299&cells,&and& treatment&with&25&µM&apigenin,&100&ng/ml&TRAIL,&or&a&combination& of& 10& µM& apigenin& and& 100& ng/ml& TRAIL& showed& no& significant& increase& in&caspaseQ8& activity& as& compared& to& the& DMSOQcontrol& (Fig.& 12B).& & Treatment&with& 25& µM&apigenin& and& 100& ng/ml& TRAIL& did& significantly& increase& caspaseQ8& activity& (Fig.& 12B,& *&
p<0.05),& suggesting& that& apigenin& and& TRAIL& combination& treatmentQinduced& apoptosis&occurs&via&the&extrinsic&pathway.&&
4.3!Mechanism!of!Apigenin!Sensitization!of!NSCLC!Cells!to!TRAIL!Treatment!
! In& order& to& investigate& the& molecular& mechanisms& by& which& apigenin& sensitizes&NSCLC& cells& to& TRAIL& treatment,& the& expression& of& apoptotic& proteins& was& assessed& by&western&blots.& &For&this&purpose,&NSCLC&cells&were&treated&with&apigenin&for&18&h&(25&and&50&µM&for&A549&and&CaluQ1,&10&and&25&µM&for&H2009&and&H1299)&prior&to&the&addition&of&100& ng/ml& TRAIL& for& 6& h.& & Immunoblot& of& A549& lysates& showed& that& XIAP& expression&decreases&by&40%&with&apigenin&treatment&compared&to&the&DMSOQcontrol&or&TRAIL&alone&
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treated& cells& (Fig.13A,& lanes& 1Q3).& & Combination& treatments& of& apigenin& and& TRAIL&decreased&XIAP&expression&to&similar&levels&found&in&apigenin&alone&treated&cells&(Fig.&13A,&lanes&4Q5&vs.&2).&&Like&A549&cells,&H2009&XIAP&expression&was&similar&in&DMSOQcontrol&and&TRAIL&treated&cells,&and&lower&in&apigenin&and&combination&treated&cells&(Fig.&13A,&lanes&6Q10).& & In& & CaluQ1& cells,& expression& of& XIAP& decreased& by& 45%&with& apigenin& treatment& as&compared& to& the& control,& increased& by& about& twofold& with& TRAIL& treatment,& and& then&decreased&again&with&the&combination&treatments&(Fig.&13A,&lanes&11Q15).&&However,&while&both&25&and&50&µM&apigenin&decreased&XIAP&expression&compared&to&the&control& in&A549&when& combined&with&100&ng/ml&TRAIL,& only& the&50&µM&apigenin&and&100&ng/ml& treated&CaluQ1& cells& showed& lower& XIAP& expression& (Fig.& 13A,& lanes& 4,& 5,& 14,& 15).& & H1299& cells&showed& a& decrease& in& XIAP& expression& with& apigenin& treatment,& no& change& with& TRAIL&treatment,& and& a& decrease& with& combination& treatments& that& was& dependent& on& the&apigenin&concentration&(Fig.&13A,& lanes&16Q20).& &The&expression&of&Hsp27&decreased&with&apigenin&treatment&and&was&unaffected&by&TRAIL&treatment&in&all&cell&lines&compared&to&the&DMSOQcontrol&(Fig.&13A,&lanes&1Q3,&6Q8,&11Q13,&16Q18).&&In&addition,&all&cell&lines&showed&an&apigenin& concentrationQdependent& decrease& in& Hsp27& expression& with& combination&treatments&(Fig.&13A,&lanes&4,&5,&9,&10,&14,&15,&19,&20).&&The&expression&of&BID,&a&member&of&the& BclQ2& family& and& a& caspaseQ8& substrate,& was& unchanged& in& samples& treated& with&apigenin&alone&compared&to&the&DMSOQcontrol&in&all&cell&lines&(Fig.&13A,&lanes&1,&2,&6,&7,&11,&12,&16,&17).&&However,&in&the&presence&of&TRAIL,&A549&and&CaluQ1&cells&showed&no&changes&in& BID& expression& compared&with& the& control,& while& H2009& and& H1299& showed& about& a&50%&decrease&of&BID&as&compared&to&the&control&(Fig.&13A,&lanes&3,&8,&13,&18).&&Apigenin&and&TRAIL&combination&treatments&greatly&reduced&the&prevalence&of&BID&in&all&cell&lines,&from&
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45&%&in&CaluQ1&cells&treated&with&50&µM&apigenin&and&100&ng/ml&TRAIL&to&98%&in&H1299&cells& treated& with& 25& µM& apigenin& and& 100& ng/ml& TRAIL,& suggesting& the& proteolytic&processing&of&BID&to&tQBID&by&caspaseQ8&(Fig.&13A,&lanes&4,&5,&9,&10,&14,&15,&19,&20).&&&Apigenin& increased& the& expression& of& DR5& in& A549& cells& in& a& concentrationQdependent&manner&as&compared&to&the&DMSOQcontrol&(Fig.&13A,&lanes&2,&4,&5&vs.&lane&1).&&In&addition,& TRAIL& treatment& had& no& effect& on& the& expression& of& DR5& (Fig.& 13A,& lane& 3).& & A&similar&effect&of&apigenin&and&TRAIL&treatments&was&observed&in&H2009,&CaluQ1,&and&H1299&cells&as&well&(Fig.&13A,&lanes&6Q20).&&Interestingly,&other&Hsps,&including&the&DR5&chaperone&Hsp70,&were&not&effected&by&apigenin&or&the&combination&treatment&of&apigenin&and&TRAIL,&unlike&Hsp27.&(Fig.&13A,&lanes&2,&4,&5,&7,&9,&10&12,&14,&15,&17,&19,&20).&&& &These&results&show&that& TRAIL& sensitization& by& apigenin& includes& the& downQregulation& of& antiQapoptotic&proteins&as&well&as&the&upQregulation&of&the&TRAIL&receptor,&DR5.&& It& was& previously& reported& that& Hsp70& associates& with& the& intracellular& death&domain& of& DR5,& thereby& blocking& DR5& signaling& and& preventing& the& activation& of& the&apoptotic& casacade& (101).& &Moreover,& silencing&of&Hsp70& sensitized& cells& to&drugQinduced&apoptosis&by&allowing&DISC&formation&on&the&DR5&receptor&(119).&&Based&on&these&findings,&it&was&hypothesized&that&apigenin&sensitizes&NSCLC&cells&to&TRAIL&by&disrupting&the&Hsp70QDR5& complex.& & To& test& this& hypothesis,& A549& and& H1299& cells& were& selected& since& they&showed& the&greatest&decrease& in&BID& levels&with&apigeninQTRAIL&combination& treatments&(Fig.&13A,&lanes&4,&5,&19,&20).&&Cell&lysates&from&A549&and&H1299&cells&treated&with&apigenin&(50& µM& for& A549& or& 25& µM& for& H1299)& for& 18& h& followed& by& 100& ng/ml& TRAIL& for& an&additional& 6& h& and& were& immunoprecipitated& with& antiQDR5& or& IgG& isotype& control&antibodies,& resolved& by& SDSQPAGE,& and& immunoblotted& with& antiQHsp70& and& antiQDR5&
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antibodies&(Fig.&13B&and&Table&3).&&The&results&showed&that&TRAIL&treatment&alone&does&not&affect&the&Hsp70QDR5&interaction&in&A549&cells,&while&it&enhances&Hsp70&binding&to&DR5&by&50%&compared&to& the&control& in&H1299&cells& (Fig.&13B,& lane&2&vs.&4).& &Apigenin&treatment&alone&decreases&Hsp70&association&to&DR5&by&more&than&70%&compared&to&the&control& in&both& cell& lines& (Fig.& 13B,& lane& 3).& & However,& a& repeat& of& this& experiment& showed& that&apigenin&alone&reduced&Hsp70&binding&by&25%,&so&while&it&is&clear&that&apigenin&is&able&to&disrupt& the& Hsp70QDR5& complex,& the& extent& to& which& this& occurs& will& require& further&investigation& (data& not& shown).& & Regardless,& the& apigenin& and& TRAIL& combination&treatment&resulted&in&a&loss&of&more&than&80%&of&Hsp70&binding&to&DR5&in&all&repeats&(Fig.&13B,&lane&5).&&Taking&the&previous&results&into&consideration,&the&data&suggest&that&apigenin&and&TRAIL&combination&treatments&not&only&increase&DR5&expression,&but&also&disrupt&the&Hsp70QDR5& complex& thereby& freeing& the& DR5& intracellular& death& domain& for& DISC&formation&and&promoting&the&activation&of&caspaseQ8,&as&shown&in&Fig.&12B.&
!
4.4!Conclusion!& In&this&project& the&ability&of& the& flavone&apigenin&to&sensitize&NSCLC&cells& to&TRAIL&treatment&was&investigated.&&Four&NSCLC&cell&lines,&A549,&H2009,&CaluQ1,&and&H1299,&were&treated&with&various&combinations&of&apigenin&and&TRAIL&and&cell&viability,&percentage&of&apoptotic& and& active& caspaseQ3& cells,& and& changes& in& apoptotic& protein& expression& was&assessed.& &Our&findings&showed&that&apigenin&sensitizes&NSCLC&to&TRAILQinduced&caspaseQ3Qdependent& apoptosis& by& increasing& the& expression& of& the& TRAIL& receptor,& DR5,& and&decreasing& the& expression& of& antiQapoptotic& proteins& like& Hsp27& and& XIAP.& & In& addition,&treatment&with&apigenin&decreased&the&association&of&Hsp70&with&DR5,&probably&facilitating&
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Figure 10. Apigenin sensitizes NSCLC to TRAIL treatment in a synergistic manner.  A: Cell 
viability of NSCLC cells treated with apigenin (Api) for 24 h and TRAIL added for an additional 24 h was 
determined by MTT assay.  The data were analyzed by two-way ANOVA and the 25 and 50 µM Api 
treatments were found to be statistically significant (p<0.0001) for all cell lines.  In addition, statistical 
significance was also determined for the 10 µM Api treatment of Calu-1 cells (p<0.0001) and the 10 µM 
Api treatment of H1299 cells (p<0.01).  B: Isobolograms of combination treatments shown in (A) with 
calculated combination index (CI <1, synergistic; CI =1, additive; CI >1, antagonistic).  Data is 
expressed as mean of three experiments ± SEM.
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Figure 11. Apigenin and TRAIL combination treatments induce caspase-3 dependent apoptosis.  
NSCLC cell lines were treated with two concentrations of apigenin (10 and 25 µM for H2009 and H1299; 25 
and 50 µM for A549 and Calu-1) or DMSO control (-) for 18 h and 25, 50, or 100 ng/ml TRAIL or TRAIL buffer 
control (-) was added for an additional 6 h.  A-B: Percentage of apoptotic cells and active caspase-3 was 
determined using Annexin V-APC/7-AAD and anti-active caspase-3-FITC staining, respectively.  Statistical 
analysis was done using two-way ANOVA to compare the effect of apigenin concentration across a range of 
TRAIL concentrations (*** p<0.001; **** p<0.0001).  TRAIL concentration was not found to have a significant 
effect within each apigenin treatment group.  Data is expressed as mean of three experiments ± SEM.  Flow 
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Figure 12. Apigenin and TRAIL combination treatments induce apoptosis via the extrinsic 
pathway.  NSCLC cell lines were treated with two concentrations of apigenin (10 and 25 µM for H2009 
and H1299; 25 and 50 µM for A549 and Calu-1) or DMSO-control (-) for 18 h prior to the addition of 25, 
50, or 100 ng/ml TRAIL or TRAIL Buffer-control (-) for 6 h.  A-B: Caspase-3 and -8 activity was 
determined using the caspase activity assays and the fluorescent substrates DEVD-AFC and 
IETD-AFC, respectively.  Statistical analysis was done using two-way ANOVA to compare the effect of 
apigenin concentration across a range of TRAIL treatments 
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Figure 13. Apigenin sensitizes NSCLC cells to TRAIL treatment via regulation of 
apoptotic protein expression.  NSCLC cells were treated with apigenin for 18 h and 
TRAIL was added for an additional 6 h.  A: Cell extracts from treated NSCLC cells were 
resolved by SDS-PAGE and immunoblotted with anti-Hsp70, anti-DR5, anti-XIAP, 
anti-Hsp27, and anti-BID.  GAPDH was used as a control for equal loading.  B: A549 and 
H1299 lysates were immunoprecipitated (IP) using anti-DR5 or IgG control antibodies 
(lane 1) and samples were analyzed by immunoblotting using anti-DR5 and anti-Hsp70 
antibodies.  The data presented is representative of two independent experiments.  IPs 







Discussion!& It&has&been&wellQestablished&that&caspaseQ3&is&an&essential&protease&for&the&execution&of&apoptosis&(12).& &Numerous&proteins&ensure&the&timely&induction&of&apoptosis&by&tightly&regulating& the& proteolytic& activation& of& caspaseQ3.& & The& activity& of& such& antiQapoptotic&proteins& as& XIAP,& BclQ2,& BclQXL,& Hsp70& and& Hsp27& prevent& apoptosis& by& inhibiting& the&pathways&that&activate&caspaseQ3&(2,28,34).&&Specifically,&our&lab&has&previously&shown&that&Hsp27&is&a&key&apoptotic&regulator&that&binds&to&caspaseQ3&to&prevent&its&activation&(21).&&&& In& this& study,& we& defined& the& Hsp27& peptide& region& that& is& responsible& for& the&inhibition&of& apoptosis&via& the& specific& interaction&with& caspaseQ3.& & First,&we& showed& that&the&Hsp27&CQterminal& is& required& for& the& association&with& caspaseQ3& and& inhibition& of& its&activity,&while&the&NQterminal&is&unable&to&bind&or&inhibit&its&activity&(Fig.&3BQD).&&Pandey,&et%
al.&have&also&shown&that&Hsp27&associates&with&caspaseQ3& (120).& & However,& Bruey,& et%
al.& were& not& able& to& show& an& interaction& between& Hsp27& and& caspaseQ3& and& suggest& an&alternative&pathway&in&which&Hsp27&antiQapoptotic&activity&relies&on&the&ability&of&Hsp27&to&bind&to&cytochrome&C,&thereby&preventing&apoptosis&upstream&of&caspaseQ3&activation&(46).&&Our& findings,& using& purified& caspaseQ3,& Hsp27,& and& active& caspaseQ9& proteins,& clearly&demonstrated&that&Hsp27&can&bind&directly&to&caspaseQ3&and&cytochrome&C&is&not&required&for& the&antiQapoptotic&activity&of&Hsp27& (Fig.&3C&and&3D).& & Indeed,&Bruey,&et%al.& show& that&Hsp27&aa&51Q88&(within&the&NQterminal)&and&Cys137&are&required&to&bind&to&cytochrome&C,&suggesting& that& the& Hsp27& CQterminal& association& with& caspaseQ3& shown& here& must& be&cytochrome& CQindependent& (46).& & It& is& widely& believed& that& Cys137,& the& only& cysteine&
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residue& in& the& Hsp27& sequence,& is& important& for& a& disulfide& bridge& leading& to& the& dimer&formation&characteristic&of&all&sHsps&(121).&&As&a&result,&Bruey,&et%al.&propose&that&Hsp27&aa&51Q88&bind& to&cytochrome&C,&but& require&an&Hsp27&dimer& (and&by&extension,&Cys137)& for&the& interaction& to& occur& (46).& & Our& results& showed& that& the& Hsp27& CQterminal,& which&includes& Cys137,& associates& with& caspaseQ3,& suggesting& that& the& Hsp27QcaspaseQ3&interaction&also&requires&Hsp27&dimer&formation.&& After&determining&that&the&Hsp27QcaspaseQ3&interaction&is&mediated&solely&through&the&Hsp27&CQterminal,&further&characterization&of&this&domain&was&performed&to&define&the&specific& Hsp27& peptide& responsible& for& binding& to& caspaseQ3& using& CQterminal& nested&deletion&clones&(Fig.5).& &The&results&of&the&IP&demonstrated&that&loss&of&Hsp27&aa&154Q186&causes& considerable& loss& (~50%)& of& Hsp27& association& to& caspaseQ3& (Fig.& 6,& lane& 4).&&Furthermore,& loss& of& Hsp27& aa& 104Q119& completely& abolished& the& Hsp27QcaspaseQ3&interaction& (Fig.& 6,& lane& 7).& & These& results& suggest& that& Hsp27& may& have& two& caspaseQ3&specific& binding& regions,& aa& 104Q119& and& aa& 154Q186.& & However,& our& findings& cannot&distinguish&whether&both&regions&contribute&equally&to&the&Hsp27QcaspsaeQ3&interaction,&or&if&one&region&is&more&important&than&the&other&using&these&clones&due&to&the&fact&that&when&aa&104Q119&is&deleted,&aa&154Q186&is&also&deleted.&&An&additional&clone&that&has&aa&104Q119&deleted&but&still& included&aa&154Q186&would&be&required&to&determine&the&contribution&of&each& binding& region.& & If& each& region& contributes& equally,& we&would& expect& to& see& a& 50%&reduction&in&Hsp27&association&to&caspaseQ3&following&deletion&of&either&region.&&However,&if& aa& 104Q119& is& more& important& binding,& we& would& expect& to& see& a& greater& loss& in& the&association&or&even&complete&abolishment&of&the&Hsp27QcaspaseQ3&complex.&&
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& The& Hsp27& clones& were& used& to& assess& if& the& decreased& association& of& Hsp27& to&caspaseQ3& impaired& the& ability& of& Hsp27& to& inhibit& caspaseQ3& activation& in& the& H9c2&cardiomyocyte&model&treated&with&doxorubicin&(Fig.&7).&&Dox&is&an&effective&and&commonly&used& chemotherapeutic& drug& that& induces& cardiomyocyte& apoptosis& as& a& side& effect& of&cancer& treatments& (22,76,82).& & Therefore,& the& goal& of& this& study&was& to&define& the&Hsp27&peptide&domain&that&regulates&caspaseQ3&activation.&&The&results&of&the&apoptosis&and&active&caspaseQ3&staining&and&caspaseQ3&activity&show&that&until&the&loss&of&aa&104Q119,&Hsp27&is&able& to& completely& inhibit& caspaseQ3& activation& and& apoptosis& (Fig.& 7A,& B,& and& C).&&Theoretically,& after& the& deletion& of& the& peptide& region& of& Hsp27& that& is& specific& for& the&association&with&caspaseQ3,&we&would&expect&to&see&a& loss&in&binding&to&caspaseQ3&but&not&necessarily&a&loss&in&the&ability&of&Hsp27&to&prevent&apoptosis&overall,&due&to&the&ability&of&Hsp27&to&halt&apoptosis&upstream&of&caspaseQ3&activation.&&Therefore,&the&ability&of&Hsp27&Δ154Q205& to& inhibit& apoptosis& (Fig.& 7A,& clone& C)& combined& with& the& observed& loss& of&caspaseQ3&binding&of&the&same&clone&(Fig.&6,&lane&4)&suggests&that&aa&154Q186&is&a&caspaseQ3&specific& binding& region.& & For& example,& Hsp27& Δ154Q205& is& likely& still& able& to& inhibit&apoptosis& and& caspaseQ3& activation& by& binding& cytochrome& C,& for& which& aa& 51Q88& and&Cys137&are&essential,&and&preventing&caspaseQ9&activation&(46).&&As&expected,&based&on&the&findings& of& Bruey,& et% al.,& Hsp27& Δ137Q205& is& not& able& to& significantly& inhibit& caspaseQ9&activity,&probably&due&to&an&inability&of&the&Hsp27&clone&to&bind&to&cytochrome&C&(Fig.&7B,&clone& D).& & Interestingly,& Hsp27& Δ137Q205& is& still& able& to& inhibit& caspaseQ3& activity& and&apoptosis,&which&is&suggestive&of&two&important&details.&&First,&these&results&suggest&that&the&Cys137&involved&in&the&oligomerization&and&dimer&formation&of&Hsp27&is&neither&required&for&Hsp27&to&associate&with&caspaseQ3&(Fig.&6,&lane&D)&nor&to&inhibit&apoptosis&and&caspaseQ3&
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activation& (Fig.& 7A,& clone& D).& & Second,& it& alludes& to& the& idea& that& Hsp27& is& inhibiting&apoptosis&downstream&of& the& interaction&with&cytochrome&C&and&prevention&of&caspaseQ9&activation,&which&therefore&must&involve&caspaseQ3,&the&substrate&of&caspaseQ9.&&Altogether,&these& results& support& the& hypothesis& that& Hsp27& contains& two& distinct& caspseQ3& binding&domains& that& contribute& unequally& to& the& protective& effect& of& Hsp27.& & The& first& binding&region& deleted& in& these& experiments,& aa& 154Q186,& merely& stabilizes& and& promotes& the&Hsp27QcaspaseQ3&interaction.&&The&second&binding&region,&aa&104Q119,&is&the&most&vital&and,&although&Hsp27&Δ120Q205& shows& considerably& less& binding& to& caspaseQ3& than&Hsp27&wt,&the& presence& of& aa& 104Q119& is& still& able& to& completely& inhibit& caspaseQ3& activation&downstream&of&caspaseQ9.&& With& two& potential& caspaseQ3& specific& binding& regions& within& Hsp27,& we& further&examined&the&Hsp27&crystal&structure&with&the&goal&of&defining&the&most&accessible&aa&that&would& be& available& for& proteinQprotein& interactions.& & Unfortunately,& only& the& Hsp27& αQcrystallin&domain&was&recently&elucidated,&which&is&unable&to&take&into&consideration&the&aa&accessibility& within& the& full,& functional& Hsp27& oligomer& (95,96).& & Therefore,& other& fully&crystallized& sHsps& were& examined& for& their& potential& to& serve& as& a& model& for& Hsp27&structure,&and&it&was&determined&that&the&archaean&Hsp16.5&is&likely&the&most&structurally&similar& to& Hsp27& (Fig.& 8A).& & Assessment& of& the& aa& accessibility& of& Hsp27& modeled& after&Hsp16.5& revealed& several& accessible& regions& within& the& two& potential& caspaseQ3& binding&domains.&&Based&upon&our&previous&results,&our&analysis&was&focused&on&Hsp27&aa&104Q119.&&Only& a& few& residues& within& this& region& were& found& to& be& more& accessible& than& the&surrounding&peptide& (aa&104Q106;& Fig.& 9B).& & Interestingly,& aa& 104Q106& corresponded& to& a&loop& that& rises& perpendicularly& from& the& planar& surface& of& the& Hsp27& oligomer& model,&
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contributing&to&the&increased&accessibility&of&those&particular&residues&(Fig.&9A).&&Depending&on&the&accuracy&of&the&Hsp27&model,&aa&104Q106&could&be&the&residues&that&directly&interact&with&caspaseQ3&to&inhibit&its&activity,&and&further&experiments&are&required&to&validate&this&hypothesis.&& Following& the& dissection& of& the& structural& role& of& Hsp27& during& its& inhibition& of&caspaseQ3&activity,&we&determined&the&function&of&Hsp27&and&other&antiQapoptotic&proteins&within&the&context&of&apoptotic&regulation&of&lung&cancer&cells.&&For&this&purpose,&the&ability&of& flavonoids&to&sensitize& the&normally&chemotherapyQresistant&NSCLC&cells&was&assessed.&&The&therapeutic&potential&of& flavonoids&has&been&widely&recognized&due&to&their&ability&to&modulate&protein&expression&and&activity&in&numerous&diseases&including&cancer&(48).&&The&flavonoid& luteolin& has& been& shown& to& induce& apoptosis& in& A549& cells& via& the& intrinsic&pathway&by&inhibiting&NFQκB&and&downregulating&BclQ2&and&BclQXL&(108).&&Other&flavonoids,&including&quercetin&and&kaempferol,&are&able& to&similarly&regulate&antiQapoptotic&proteins&such&as&BclQ2,&though&without&the&addition&of&a&chemotherapeutic&drug,&they&lack&the&ability&to&induce&apoptosis&(105,106).&&Apigenin&has&been&shown&to&play&both&roles&with&its&ability&to& induce&apoptosis& independently& in& leukemia&cells&and&sensitize&cervical& cancer&cells& to&chemotherapeutic& treatment& (61,109).& & The& possibility& of& this& dual&mechanism& of& action&suggests& that& different& flavonoids& will& have& different& effects& depending& on& the& cell& type&being&treated.&& In& this&study&we&examined& the&effect&of&apigenin&on&NSCLC&cells.& &We&showed& that&apigenin,&up&to&50&µM&in&A549&and&CaluQ1&cells&and&25&µM&in&H2009&and&H1299&cells,&has&relatively&little&effect&on&cell&viability&and&does&not&induce&apoptosis&in&four&different&NSCLC&cell&lines&(Fig.&10A,&and&11A).&&This&is&in&agreement&with&other&findings&that&show&apigenin&
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does& not& cause& cell& death& in& lung& cancer& cells& at& similar& concentrations& (122,123).&&Interestingly,& others& have& shown& that& apigenin& concentrations& two& to& four& times& higher&than&those&used&in&this&study&are&able&to&induce&apoptosis&in&A549&cells&(123).&&Also&of&note,&50&µM&apigenin&has&been&shown& to& induce&greater& than&50%&cell&death& in& leukemia& cells&and& other& solid& epithelial& cancers& including& prostate,& breast,& and& cervical& cancer& cells&(63,124Q126).& & This& suggests& that&NSCLC& cells& are&uniquely& resistant& to& apigeninQinduced&apoptosis.&& Since&apigenin&is&unable&to&kill&NSCLC&cells&on&its&own,&we&examined&other&ways&in&which& it&may&aid& in& the& treatment&of& lung&cancers.& &As&mentioned&above,& flavonoids&have&been& shown& to& sensitize& cancer& cells& to& chemotherapy& drugs& like& dox& and& cisplatin&(105,106).&&Specifically,&apigenin&sensitizes&cervical&cancer&cells&to&TRAIL&treatment&(109).&&This&study&focused&on&the&chemotherapy&drug&TRAIL&due&to&its&remarkable&ability&to&induce&apoptosis& in& cancerous& cells& without& causing& adverse& side& effects& in& normal& cells& (97Q99,127).&&However,&our&results&showed&that&TRAIL&alone&is&not&able&to&induce&apoptosis&in&NSCLC&cells&(Fig.&10A&and&11A),&which&is&in&agreement&with&others&(83,128).&&Our&findings&showed& that& apigenin& and& TRAIL& combination& treatments& induce& significantly& more&apoptosis&in&NSCLC&cells&than&TRAIL&treatment&alone&(Fig.&10&and&11).& &Although&apigenin&and& TRAIL& combination& treatments& have& not& been& studied& in& NSCLC& cells,& a& similar&sensitization&effect&has&been&shown&in&leukemia,&hepatocellular&carcinoma,&melanoma,&and&prostate,&colon,&breast,&and&pancreatic&cancers&(117,129).&&Altogether,&these&results&suggest&that&the&ability&of&apigenin&to&sensitize&cells&to&TRAIL&treatment&is&not&limited&to&just&NSCLC&cells,& but& can& be& applied& to& a& variety& of& cancers.& & In& addition,& our& results& show& that& the&concentration&of&apigenin,&not&TRAIL,&is&the&more&important&determinant&of&the&efficacy&of&
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the&combination&treatment&(Fig.&11A).&&For&each&cell&line,&increasing&apigenin&concentration&resulted& in& significantly&more& apoptosis,& while& increasing& TRAIL& concentration& had& little&effect&on&the&level&of&apoptosis.&& After&determining&that&apigenin&is&able&to&sensitize&NSCLC&cells&to&TRAIL&treatment,&we& investigated&the&mechanism&by&which&the&sensitization&occurs.& &Previous&studies&have&described& sensitization& mechanisms& involving& changes& in& apoptotic& protein& expression&(105Q107,109,114,116Q118,128,129).& &Our&results& showed& that&apigenin& treatment&causes&an&upregulation&of& the&TRAIL& receptor&DR5& (Fig.& 13A).& &Horinaka,&et% al.& have& shown& that&apigenin& induces& increased& expression& of& DR5& leading& to& increased& sensitivity& of& TRAIL&treatment&(117).&&Quercetin&and&the&flavonone&naringenin&were&also&found&to&increase&DR5&expression&in&NSCLC&for&greater&sensitivity&to&TRAIL&(116,118).&&Decreased&IAP&expression,&including&XIAP&and&Survivin,&has&also&been&shown&to&be&caused&by&luteolin,&quercetin&and&genistein& in& lung& cancer& cells& (106,114,116).& & Our& results& show& that& apigenin& also&downregulates&XIAP&expression&(Fig.&13A,&lanes&2,&7,&12,&and&17).&&As&previously&mentioned,&Hsp27& is& another& antiQapoptotic& protein& important& for& the& resistance& to& chemotherapy&drugs& (110).& & Quercetin,& kaempferol,& and& luteolin& reduce& Hsp27& expression& in& leukemia,&cervical&cancer,&and&lung&cancer&(111Q113).&&Our&results&indicate&that&apigenin&is&also&able&to&downregulate&Hsp27&in&NSCLC&cells&(Fig.&13A,&lanes&2,&7,&12,&and&17).&&Together,&this&data&contributes& to& a&mechanism& for& apigenin& sensitization.& &The& increased&expression&of&DR5&would& increase& the& ability& of& TRAIL& to& signal& the& cell& to& undergo& apoptosis,& and& the&decreased& expression& of& Hsp27& and& XIAP& would& further& facilitate& the& activation& of& the&apoptotic&signal&cascade&to&activate&caspaseQ3.&
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& Our&data&showed&apigenin&increases&DR5&expression,&though&Hsp70&has&been&shown&to& bind& to& the&DR5& intracellular& death& domain& thereby&preventing& formation& of& the&DISC&complex&and&activation&of&caspaseQ8&(101).&&Therefore,&we&hypothesized&that&apigenin&could&promote& apoptosis& by& disrupting& the& binding& of& Hsp70& to& DR5.& & Our& data& showed& that&apigenin&decreases&Hsp70&binding&to&DR5,&though&the&extent&to&which&this&occurs&requires&further& investigation,& which& is& enhanced& even& further& when& combined& with& TRAIL&treatment& (Fig.& 13B,& lanes& 3& and& 5).& & The& disruption& of&Hsp70& binding& to&DR5& is& a& novel&mechanism&for&the&sensitization&of&cancer&cells&by&flavonoids.&&If&the&increased&expression&of&DR5& is& important& for& the& amplification& of& the& TRAIL& apoptotic& signal,& then& it& can& be&suggested& by& corollary& that& increased& availability& of& the& intracellular& death& domain& is&equally&as&integral&for&chemotherapy&sensitivity.&&This&supports&the&idea&that&apigenin&and&TRAIL&function&synergistically,&where&apigenin&is&“priming”&the&cells&for&apoptosis&without&inducing& cell& death,& while& TRAIL& is& the& “trigger”& that& initiates& the& apoptotic& cascade.&&Apigenin& and& TRAIL& are& each& unable& to& kill& cells& independently& since& neither& the& upQregulation&of&DR5&and& liberation&of& its&death&domain& from&Hsp70&caused&by&apigenin&nor&TRAIL&in&the&presence&of&low&levels&of&Hsp70Qbound&DR5&is&sufficient&to&initiate&apoptosis.&&Both& pieces,& the& priming& by& apigenin& and& the& addition& of& TRAIL& are& required& for& the&successful&induction&of&the&apoptoticQsignaling&cascade.&& The& goals& of& this& thesis&were& to& define& the&mechanisms& by&which& proteins& inhibit&apoptosis.&&For&this&purpose,&two&distinct&yet&complimentary&approaches&were&taken.&&First,&the& specific& proteinQprotein& interaction& between& caspaseQ3& and& Hsp27& was& studied& to&determine&the&Hsp27&peptide&region&responsible&for&associating&with&caspaseQ3&to&prevent&its& activation.& & We& discovered& that& Hsp27& aa& 104Q119& is& essential& for& the& inhibition& of&
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Figure 14. Proposed model for the apigenin sensitization of cancer cells and the 
structural role of Hsp27 during the inhibition of apoptosis.  Apigenin causes the increased 
expression of the TRAIL receptor DR5 (green arrow) and the decreased expression of the 
anti-apoptotic XIAP and Hsp27 (red arrow).  In addition, apigenin inhibitis the binding of Hsp70 
to the intracellular death domain of DR5.  Hsp27 inhibits apoptosis by associating with 
caspase-3.  Specifically, Hsp27 aa 104-119 and 154-186 interact with the caspase-3 prodomain 
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